Molecular Microbiology (Virology)
Institute of Medical Microbiology and Hygiene
University Regensburg

Publications

Legend: Original article,  Review,   Comment,   German article * Equal contribution, # Corresponding author
  • NECKERMANN P, MOHR M, BILLMEIER M, KARLAS A, BOILESEN DR, THIRION C, HOLST PJ, JORDAN I, SANDIG V, ASBACH B, WAGNER R#. Transgene expression knock-down in recombinant Modified Vaccinia virus Ankara vectors improves genetic stability and sustained transgene maintenance across multiple passages. Front. Immunol. 2024 Feb 6; 15:1338492. [abstract]
  • DARADOUMIS J*#, MÜLLER MD#, NECKERMANN P, ASBACH B, SCHRÖDEL S, THIRION C, WAGNER R, THOR STRATEN P, HOLST PJ#, BOILESEN D*#. Preferential Expansion of HPV16 E1-Specific T Cells from Healthy Donors’ PBMCs after Ex Vivo Immunization with an E1E2E6E7 Fusion Antigen. Cancers. 2023; 15(24):5863 https://doi.org/10.3390/cancers15245863 [abstract]
  • PRELOG M*, JESKE SD*, ASAM C*, FUCHS A*, WIESER A, GALL C, WYTOPIL M, MUELLER-SCHMUCKER SM, BEILEKE S, GOEKKAYA M, KLING E, GELDMACHER C, RUBIO-ACERO R, PLANK M, CHRISTA C, WILLMANN A, VU M, EINHAUSER S, WEPS M, LAMPL BMJ, ALMANZAR G, KOUSHA K, SCHWÄGERL V, LIEBL B, WEBER B, DRESCHER J, SCHEIDT J, GEFELLER O, MESSMANN H, PROTZER U, LIESE J, HOELSCHER M, WAGNER R, ÜBERLA K, STEININGER P#, on behalf of the CoVaKo Study Group. Clinical and immunological benefits of full primary COVID-19 vaccination in individuals with SARS-CoV-2 breakthrough infections: A prospective cohort study in non-hospitalized adults. Journal of Clinical Virology 170 (2024) 105622 https://doi.org/10.1016/j.jcv.2023.105622. [abstract]
  • MALIQI L, FRIEDRICH N, GLÖGL M, SCHMUTZ S, SCHMIDT D, RUSERT P, SCHANZ M, ZAHERI M, PASIN C, NIKLAUS C, FOULKES C, REINBERG T, DREIER B, ABELA I, PETERHOFF D, HAUSER A, KOUYOS RD, GÜNTHARD HF, VAN GILS MJ, SANDERS RW, WAGNER R, PLÜCKTHUN A, TRKOLA A. Assessing immunogenicity barriers of the HIV-1 envelope trimer. NPJ Vaccines. 2023 Sep 30;8(1):148 https://doi: 10.1038/s41541-023-00746-3. [abstract]
  • PERDIGUERO B*, HAUSER A*, GÓMEZ C E*, PETERHOFF D, SIDERIS E, SORZANO C Ó S, WILMSCHEN S, SCHABER M, STENGEL L, ASBACH B, DING S, VON LAER D, LEVY Y, PANTALEO G, KIMPEL J, ESTEBAN M#, WAGNER R#. Potency and durability of T and B cell immune responses after homologous and heterologous vector delivery of a trimer-stabilized, membrane-displayed HIV-1 clade ConC Env protein. Frontiers in Immunology 14 (2023) https://doi.org/10.3389/fimmu.2023.1270908 [abstract]
  • PETERHOFF D#, WIEGREBE S, EINHAUSER S, PATT A J, BEILEKE S, GÜNTHER F, STEININGER P, NILLER H H, BURKHARDT R, KÜCHENHOFF H, GEFELLER O, ÜBERLA K, HEID I M, WAGNER R#. Population-based study of the durability of humoral immunity after SARS-CoV-2 infection. Frontiers in Immunology 14 (2023). https://doi.org/10.3389/fimmu.2023.1242536 [abstract]
  • BARBEY C*, SU J*, BILLMEIER M, STEFAN N, BESTER R, CARNELL G, TEMPERTON N, HEENEY J, PROTZER U, BREUNIG M, WAGNER R*, PETERHOFF D*#.Immunogenicity of a silica nanoparticle-based SARS-CoV-2 vaccine in mice. European Journal of Pharmaceutics and Biopharmaceutics 192 (2023), 41-55. https://doi.org/10.1016/j.ejpb.2023.09.015. [abstract]
  • VISHWANATH S, CARNELL GW, FERRARI M, ASBACH B, BILLMEIER M, GEORGE C, SUAU SANS M, NADESALINGAM A, QINGZHOU HUANG C, PALONIEMI M, STEWART H, CHAN A, WELLS DA, NECKERMANN P, PETERHOFF D, EINHAUSER S, CANTONI D, MAYORA NETO M, JORDAN I, SANDIG V, TONKS P, TEMPERTON N, FROST S, SOHR K, LLUESMA BALLESTEROS MT, ARBABI F, GEIGER J, DOHMEN C, PLANK C, KINSLEY R, WAGNER R, HEENEY JL#. A computationally designed antigen eliciting broad humoral responses against SARS-CoV-2 and related sarbecoviruses. Nat. Biomed. Eng (2023). https://doi.org/10.1038/s41551-023-01094-2. [abstract]
  • The COVID-19 Host Genetics Initiative. A second update on mapping the human genetic architecture of COVID-19. Nature 621, E7–E26. 2023 Sept 06. https://doi.org/10.1038/s41586-023-06355-3. [abstract]
  • SKANDORFF I, GILLE J, RAGONNAUD E, ANDERSSON AM, SCHRÖDEL S, THIRION C, WAGNER R, HOLST PJ#. (2023) The Insertion of an Evolutionary Lost Four-Amino-Acid Cytoplasmic Tail Peptide into a Syncytin-1 Vaccine Increases T- and B-Cell Responses in Mice. Viruses. 2023 Aug 3;15(8):1686. doi: 10.3390/v15081686. [abstract]
  • SKANDORFF I, RAGONNAUD E, GILLE J, ANDERSSON AM, SCHRÖDEL S, DUVNJAK L, TURNER L, THIRION C, WAGNER R, HOLST PJ#. (2023) Human Ad19a/64 HERV-W Vaccines Uncover Immunosuppression Domain-Dependent T-Cell Response Differences in Inbred Mice. Int J Mol Sci. 2023 Jun 9;24(12):9972. [abstract]
  • MONFERRER A, KOHLER F, SIGL C, SCHACHTNER M, PETERHOFF D, ASBACH B, WAGNER R, DIETZ H.# (2023) DNA origami traps for large viruses. Cell Reports Physical Science. 2023 Jan 18; 4(1). [abstract]
  • STREIF S, NECKERMANN P, SPITZENBERG C, WEISS K, HOECHERL K, KULIKOWSKI K, HAHNER S, NOELTING C, EINHAUSER S, PETERHOFF D, ASAM C, WAGNER R, BAEUMNER AJ#. (2023) Liposome-based high-throughput and point-of-care assays toward the quick, simple, and sensitive detection of neutralizing antibodies against SARS-CoV-2 in patient sera. Anal Bioanal Chem. 2023 Mar;415(8):1421-1435. [abstract]
  • CARNELL GW*, BILLMEIER M*, VISHWANATH S*, SUAU SANS M, WEIN H, GEORGE CL, NECKERMANN P, DEL ROSARIO JMM, SAMPSON AT, EINHAUSER S, AGUINAM ET, FERRARI M, TONKS P, NADESALINGAM A, SCHÜTZ A, HUANG CQ, WELLS DA, PALONIEMI M, JORDAN I, CANTONI D, PETERHOFF D, ASBACH B, SANDIG V, TEMPERTON N, KINSLEY R, WAGNER R*#, HEENEY JL*#. (2023) Glycan masking of a non-neutralising epitope enhances neutralising antibodies targeting the RBD of SARS-CoV-2 and its variants. Front Immunol. 2023 Feb 23;14:1118523 [abstract]
  • MEIER JP, MÖBUS S, HEIGL F, ASBACH-NITZSCHE A, NILLER HH, PLENTZ A, AVSAR K, HEIß-NEUMANN M, SCHAAF B, CASSENS U, SEESE B, TESCHNER D, HANDZHIEV S, GRAF U, LÜBBERT C, STEINMAURER M, KONTOGIANNI K, BERG C, MAIERON A, BLAAS SH, WAGNER R, DEML L#, BARABAS S. (2023) Performance of T-Track® TB, a Novel Dual Marker RT-qPCR-Based Whole-Blood Test for Improved Detection of Active Tuberculosis. Diagnostics (Basel). 2023 Feb 16;13(4):758. [abstract]
  • BOILESEN DR*, NECKERMANN P*, WILLERT T, MÜLLER MD, SCHRÖDEL S, PERTL C, THIRION C, ASBACH B, WAGNER R*#, HOLST PJ*#. (2022) Efficacy and synergy with cisplatin of an adenovirus vectored therapeutic E1E2E6E7 vaccine against HPV genome positive C3 cancers in mice. Cancer Immunol Res. 2023 Feb 3;11(2):261-275. [abstract]
  • NADESALINGAM A, CANTONI D, AGUINAM ET, CHAN AC, PALONIEMI M, OHLENDORF L, GEORGE C, CARNELL G, LYALL J, FERRARI M, TEMPERTON N, WAGNER R, CASTILLO-OLIVARES J, BAXENDALE H, HEENEY JL#. (2023) Vaccination and protective immunity to SARS-CoV-2 omicron variants in people with immunodeficiencies. Lancet Microbe. 2023 Feb;4(2):e58-e59. [abstract]
  • HORVATH A, ROGERS L, POLLAKIS G, BARANOV O, PIEROTH N, JOSEPH S, CHACHAGE M, HEITZER A, MAGANGA L, MSAFIRI F, JOACHIM A, VIEGAS E, ELLER LA, KIBUUKA H, RERKS-NGARM S, PITISUTTITHUM P, NITAYAPAN S, DHITAVAT J, PREMSRI N, FIDLER S, SHATTOCK RJ, ROBB ML, WEBER J, MCCORMACK S, MUNSERI PJ, LYAMUYA E, NILSSON C, KROIDL A, HOELSCHER M, WAGNER R, GELDMACHER C*, HELD K*#. (2023) Systematic comparison of HIV-1 Envelope-specific IgG responses induced by different vaccination regimens: Can we steer IgG recognition towards regions of viral vulnerability? Front Immunol. 2023 Jan 9;13:1075606. [abstract]
  • STANZICK KJ, SIMON J, ZIMMERMANN ME, SCHACHTNER M, PETERHOFF D, NILLER HH, ÜBERLA K, WAGNER R, HEID IM, STARK KJ. (2023) DNA extraction from clotted blood in genotyping quality. Biotechniques. 2023 Jan;74(1):23-29. [abstract]
  • GÜNTHER F, EINHAUSER S, PETERHOFF D, WIEGREBE S, NILLER HH, BEILEKE S, STEININGER P, BURKHARDT R, KÜCHENHOFF H, GEFELLER O, ÜBERLA K, HEID IM#, WAGNER R#. (2022) Higher Infection Risk among Health Care Workers and Lower Risk among Smokers Persistent across SARS-CoV-2 Waves-Longitudinal Results from the Population-Based TiKoCo Seroprevalence Study. Int J Environ Res Public Health. 2022 Dec 17;19(24):16996.[abstract]
  • PETERHOFF D#, THALHAUSER S, NECKERMANN P, BARBEY C, STRAUB K, NAZET J, MERKL R, LAENGST G, BREUNIG M#, WAGNER R#. (2022) Multivalent display of engineered HIV-1 envelope trimers on silica nanoparticles for targeting and in vitro activation of germline VRC01 B cells. Eur J Pharm Biopharm. 2022 Dec;181:88-101.[abstract]
  • GLÜCK V, TYDYKOV L, MADER AL, WARDA AS, BERTOK M, WEIDLICH T, GOTTWALD C, KÖSTLER J, SALZBERGER B, WAGNER R, KOLLER M, GESSNER A, SCHMIDT B, GLÜCK T, PETERHOFF D#. (2022) Humoral immunity in dually vaccinated SARS-CoV-2-naïve individuals and in booster-vaccinated COVID-19-convalescent subjects. 2022 Dec;50(6):1475-1481.[abstract]
  • NADESALINGAM A, CANTONI D, AGUINAM ET, CHAN AC, PALONIEMI M, OHLENDORF L, GEORGE C, CARNELL G, LYALL J, FERRARI M, TEMPERTON N, WAGNER R, CASTILLO-OLIVARES J, BAXENDALE H, HEENEY JL#. (2022) Vaccination and protective immunity to SARS-CoV-2 omicron variants in people with immunodeficiencies. Lancet Microbe. 2022 Nov 1:S2666-5247(22)00297-X.[abstract]
  • HUPF J#, BURKHARDT R, GESSNER A, MAIER-STOCKER C, ZIMMERMANN M, HANSES F*, PETERHOFF D*. (2022) Low incidence of SARS-CoV-2 infections in healthcare workers at a tertiary care hospital: Results of a prospective serological cohort study of the first and second COVID 19 pandemic wave. [Article in German] Med Klin Intensivmed Notfmed. 2022 Nov;117(8):639-643.[abstract]
  • BAUERNFEIND S#, EINHAUSER S, TYDYKOV L, MADER AL, SALZBERGER B, HITZENBICHLER F, MOHR A, BURKHARDT R, WAGNER R, PETERHOFF D. (2022) Association between Adverse Reactions and Humoral Immune Response No Longer Detectable after BNT162b2 Booster Vaccination. Vaccines (Basel). 2022 Sep 25;10(10):1608.[abstract]
  • DA COSTA KAS*, DEL ROSARIO JMM*, FERRARI M, VISHWANATH S, ASBACH B, KINSLEY R, WAGNER R, HEENEY JL, CARNELL GW, TEMPERTON NJ#. (2022) Influenza A (N1-N9) and Influenza B (B/Victoria and B/Yamagata) Neuraminidase Pseudotypes as Tools for Pandemic Preparedness and Improved Influenza Vaccine Design. Vaccines (Basel). 2022 Sep 14;10(9):1520.[abstract]
  • MAGNUS CL, HIERGEIST A, SCHUSTER P, ROHRHOFER A, MEDENBACH J, GESSNER A, PETERHOFF D*, SCHMIDT B*#. (2022) Targeted escape of SARS-CoV-2 in vitro from monoclonal antibody S309, the precursor of sotrovimab. Front Immunol. 2022 Aug 24;13:966236.[abstract]
  • STAM JC#, DE MAAT S, DE JONG D, ARENS M, VAN LINT F, GHARU L, VAN ROOSMALEN MH, ROOVERS RC, STROKAPPE NM, WAGNER R, KLICHE A, DE HAARD HJ, VAN BERGEN EN HENEGOUWEN PM, NIJHUIS M, VERRIPS CT.(2022) Directing HIV-1 for degradation by non-target cells, using bi-specific single-chain llama antibodies. Sci Rep. 2022 Aug 4;12(1):13413.[abstract]
  • PERDIGUERO B*, ASBACH B*, GÓMEZ CE, KÖSTLER J, BARNETT SW, KOUTSOUKOS M, WEISS DE, CRISTILLO AD, FOULDS KE, ROEDERER M, MONTEFIORI DC, YATES NL, FERRARI G, SHEN X, SAWANT S, TOMARAS GD, SATO A, FULP WJ, GOTTARDO R, DING S, HEENEY JL, PANTALEO G, ESTEBAN M#, WAGNER R#. (2022) Early and Long-Term HIV-1 Immunogenicity Induced in Macaques by the Combined Administration of DNA, NYVAC and Env Protein-Based Vaccine Candidates: The AUP512 Study. Front Immunol. 2022 Jul 22;13:939627.[abstract]
  • EINHAUSER S, PETERHOFF D, BEILEKE S, GÜNTHER F, NILLER HH, STEININGER P, KNÖLL A, KORN K, BERR M, SCHÜTZ A, WIEGREBE S, STARK KJ, GESSNER A, BURKHARDT R, KABESCH M, SCHEDL H, KÜCHENHOFF H, PFAHLBERG AB, HEID IM, GEFELLER O, ÜBERLA K*#, WAGNER R*#. (2022) Time Trend in SARS-CoV-2 Seropositivity, Surveillance Detection- and Infection Fatality Ratio until Spring 2021 in the Tirschenreuth County-Results from a Population-Based Longitudinal Study in Germany. Viruses. 2022 May 27;14(6):1168. doi: 10.3390/v14061168.[abstract]
  • CANTONI D, MAYORA-NETO M, NADESALINGAM A, WELLS DA, CARNELL GW, OHLENDORF L, FERRARI M, PALMER P, CHAN ACY, SMITH P, BENTLEY EM, EINHAUSER S, WAGNER R, PAGE M, RADDI G, BAXENDALE H*, CASTILLO-OLIVARES J*, HEENEY J*#, TEMPERTON N*#. (2022) Neutralisation Hierarchy of SARS-CoV-2 Variants of Concern Using Standardised, Quantitative Neutralisation Assays Reveals a Correlation With Disease Severity; Towards Deciphering Protective Antibody Thresholds. Front Immunol. 2022 Mar 7;13:773982. doi: 10.3389/fimmu.2022.773982.[abstract]
  • MADER AL*, TYDYKOV L*, GLÜCK V*, BERTOK M, WEIDLICH T, GOTTWALD C, STEFL A, VOGEL M, PLENTZ A, KÖSTLER J, SALZBERGER B, WENZEL JJ, NILLER HH, JANTSCH J, WAGNER R, SCHMIDT B, GLÜCK T, GESSNER A, PETERHOFF D#. (2022) Omicron’s binding to Sotrovimab, Casirivimab, Imdevimab, CR3022, and sera from previously infected or vaccinated individuals. iScience. 2022 Mar 14:104076. doi: 10.1016/j.isci.2022.104076.[abstract]
  • PETERHOFF D*, EINHAUSER S*, BEILEKE S*, NILLER HH, GÜNTHER F, SCHACHTNER M, ASBACH B, STEININGER P, TENBUSCH M, PETER AS, GESSNER A, BURKHARDT R, HEID IM, WAGNER R*#, ÜBERLA K*#. (2022) Comparative Immunogenicity of COVID-19 Vaccines in a Population-Based Cohort Study with SARS-CoV-2-Infected and Uninfected Participants. Vaccines (Basel). 2022 Feb 18;10(2):324. doi: 10.3390/vaccines10020324.[abstract]
  • NEUMANN B, ANGSTWURM K, LINKER RA, KNOLL G, EIDENSCHINK L, RUBBENSTROTH D, SCHLOTTAU K, BEER M, SCHREINER P, SOUTSCHEK E, BÖHMER MM, LAMPL BMJ, PREGLER M, SCHEITER A, EVERT K, ZOUBAA S, RIEMENSCHNEIDER MJ, ASBACH B, GESSNER A, NILLER HH, SCHMIDT B, BAUSWEIN M#. (2022) Antibodies against viral nucleo-, phospho-, and X protein contribute to serological diagnosis of fatal Borna disease virus 1 infections. Cell Rep Med. 2022 Jan 18;3(1):100499. doi: 10.1016/j.xcrm.2021.100499. eCollection 2022 Jan 18.[abstract]
  • BAUSWEIN M*#, PETERHOFF D*, PLENTZ A*, HIERGEIST A, WAGNER R, GESSNER A, SALZBERGER B, SCHMIDT B, BAUERNFEIND S. (2022) Neutralization of SARS-CoV-2 Delta variant is increased after heterologous ChAdOx1 nCoV-19/BNT162b2 versus homologous BNT162b2 vaccination. iScience. 2022 Jan 5:103694. doi: 10.1016/j.isci.2021.103694.[abstract]
  • WAGNER R, ASBACH B. [When will there finally be a vaccine against HIV?]. MMW Fortschr Med. 2022 Jun;164(Suppl 2):30-33. doi: 10.1007/s15006-022-1022-9. [link]
  • VALERO J*#, CIVIT L*, DUPONT DM, SELNIHHIN D, REINERT LS, IDORN M, ISRAELS BA, BEDNARZ AM, BUS C, ASBACH B, PETERHOFF D, PEDERSEN FS, BIRKEDAL V, WAGNER R, PALUDAN SR, KJEMS J#. (2021) A serum-stable RNA aptamer specific for SARS-CoV-2 neutralizes viral entry. Proc Natl Acad Sci U S A. 2021 Dec 14;118(50):e2112942118.[abstract]
  • CASTILLO-OLIVARES J#, WELLS DA, FERRARI M, CHAN ACY, SMITH P, NADESALINGAM A, PALONIEMI M, CARNELL GW, OHLENDORF L, CANTONI D, MAYORA-NETO M, PALMER P, TONKS P, TEMPERTON NJ, PETERHOFF D, NECKERMANN P, WAGNER R, DOFFINGER R, KEMPSTER S, OTTER AD, SEMPER A, BROOKS T, ALBECKA A, JAMES LC, PAGE M, SCHWAEBLE W, BAXENDALE H*, HEENEY JL*. (2021) Analysis of Serological Biomarkers of SARS-CoV-2 Infection in Convalescent Samples From Severe, Moderate and Mild COVID-19 Cases. Front Immunol. 2021 Nov 19;12:748291.[abstract]
  • SISKA PJ, DECKING SM*, BABL N*, MATOS C*, BRUSS C, SINGER K, KLITZKE J, SCHÖN M, SIMETH J, KÖSTLER J, SIEGMUND H, UGELE I, PAULUS M, DIETL A, KOLODOVA K, STEINES L, FREITAG K, PEUKER A, SCHÖNHAMMER G, RAITHEL J, GRAF B, GEISMANN F, LUBNOW M, MACK M, HAU P, BOHR C, BURKHARDT R, GESSNER A, SALZBERGER B, WAGNER R, HANSES F, HITZENBICHLER F, HEUDOBLER D, LÜKE F, PUKROP T, HERR W, WOLFF D, SPANG R, POECK H, HOFFMANN P, JANTSCH J, BROCHHAUSEN C, LUNZ D, REHLI M, KREUTZ M*#, RENNER K*. (2021) Metabolic imbalance of T cells in COVID-19 is hallmarked by basigin and mitigated by dexamethasone. J Clin Invest. 2021 Nov 15;131(22):e148225.[abstract]
  • NECKERMANN P*, BOILESEN DR*, WILLERT T, PERTL C, SCHRÖDEL S, THIRION C, ASBACH B, HOLST PJ#, WAGNER R#. (2021) Design and Immunological Validation of Macaca fascicularis Papillomavirus Type 3 Based Vaccine Candidates in Outbred Mice: Basis for Future Testing of a Therapeutic Papillomavirus Vaccine in NHPs. Front Immunol. 2021 Oct 28;12:761214.[abstract]
  • EINHAUSER S*, PETERHOFF D*, NILLER HH, BEILEKE S, GÜNTHER F, STEININGER P, BURKHARDT R, HEID IM, PFAHLBERG AB, ÜBERLA K, GEFELLER O*#, WAGNER R*#. (2021) Spectrum Bias and Individual Strengths of SARS-CoV-2 Serological Tests-A Population-Based Evaluation. Diagnostics (Basel). 2021 Oct 6;11(10):1843. [abstract]
  • LAUB O*, LEIPOLD G*, TONCHEVA AA*, PETERHOFF D*, EINHAUSER S*, NECKERMANN P, BORCHERS N, SANTOS-VALENTE E, KHEIRODDIN P, BUNTROCK-DÖPKE H, LAUB S, SCHÖBERL P, SCHWEIGER-KABESCH A, EWALD D, HORN M, NIGGEL J, AMBROSCH A, ÜBERLA K, GERLING S, BRANDSTETTER S, WAGNER R*, KABESCH M*#; Corona Virus Antibodies in Children from Bavaria (CoKiBa) Study Group. (2021) Symptoms, SARS-CoV-2 Antibodies, and Neutralization Capacity in a Cross Sectional-Population of German Children. Front Pediatr. 2021 Oct 4;9:678937. [abstract]
  • BAUERNFEIND S#, SALZBERGER B, HITZENBICHLER F, SCIGALA K, EINHAUSER S, WAGNER R, GESSNER A, KOESTLER J*, PETERHOFF D*. (2021) Association between Reactogenicity and Immunogenicity after Vaccination with BNT162b2. Vaccines (Basel). 2021 Sep 27;9(10):1089. doi: 10.3390/vaccines9101089.[abstract]
  • GLÜCK V, GROBECKER S, KÖSTLER J, TYDYKOV L, BERTOK M, WEIDLICH T, GOTTWALD C, SALZBERGER B, WAGNER R, ZEMAN F, KOLLER M, GESSNER A, SCHMIDT B, GLÜCK T, PETERHOFF D#. (2021) Immunity after COVID-19 and vaccination: follow-up study over 1 year among medical personnel. 2021 Sep 25.[abstract]
  • BUDER F, BAUSWEIN M, MAGNUS CL, AUDEBERT F, LANG H, KUNDEL C, DISTLER K, REUSCHEL E, LUBNOW M, MÜLLER T, LUNZ D, GRAF B, SCHMID S, MÜLLER M, POECK H, HANSES F, SALZBERGER B, PETERHOFF D, WENZEL JJ, SCHMIDT B, LAMPL BMJ#. (2021) SARS-CoV-2 infectivity correlates with high viral loads and detection of viral antigen and is terminated by seroconversion. J Infect Dis. 2021 Aug 24:jiab415.[abstract]
  • SAMPSON AT#, HEENEY J, CANTONI D, FERRARI M, SANS MS, GEORGE C, DI GENOVA C, MAYORA NETO M, EINHAUSER S, ASBACH B, WAGNER R, BAXENDALE H, TEMPERTON N*, CARNELL G*. (2021) Coronavirus Pseudotypes for All Circulating Human Coronaviruses for Quantification of Cross-Neutralizing Antibody Responses. 2021 Aug 10;13(8):1579.[abstract]
  • PETER AS*, ROTH E*, SCHULZ SR, FRAEDRICH K, STEINMETZ T, DAMM D, HAUKE M, RICHEL E, MUELLER-SCHMUCKER S, HABENICHT K, EBERLEIN V, ISSMAIL L, UHLIG N, DOLLES S, GRÜNER E, PETERHOFF D, CIESEK S, HOFFMANN M, PÖHLMANN S, MCKAY PF, SHATTOCK RJ, WÖLFEL R, SOCHER E, WAGNER R, EICHLER J, STICHT H, SCHUH W, NEIPEL F, ENSSER A, MIELENZ D, TENBUSCH M, WINKLER TH, GRUNWALD T, ÜBERLA K#, JÄCK HM#. (2021) A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model. Eur J Immunol. 2021 Aug 6. doi: 10.1002/eji.202149374.[abstract]
  • HAUSER A, CARNELL G, HELD K, SULBARAN G, TISCHBIEREK N, ROGERS L, POLLAKIS G, TONKS P, HOELSCHER M, DING S, SANDERS RW, GELDMACHER C, SATTENTAU Q, WEISSENHORN W, HEENEY JL, PETERHOFF D, WAGNER R#. (2021) Stepwise Conformational Stabilization of a HIV-1 Clade C Consensus Envelope Trimer Immunogen Impacts the Profile of Vaccine-Induced Antibody Responses. Vaccines (Basel). 2021 Jul 6;9(7):750. doi: 10.3390/vaccines9070750.[abstract]
  • DEL ROSARIO JMM*, DA COSTA KAS*, ASBACH B, FERRARA F, FERRARI M, WELLS DA, MANN GS, AMEH VO, SABETA CT, BANYARD AC, KINSLEY R, SCOTT SD, WAGNER R, HEENEY JL, CARNELL GW, TEMPERTON NJ#. (2021) Exploiting Pan Influenza A and Pan Influenza B Pseudotype Libraries for Efficient Vaccine Antigen Selection. Vaccines (Basel). 2021 Jul 5;9(7):741. doi: 10.3390/vaccines9070741. [abstract]
  • NADESALINGAM A, CANTONI D, WELLS DA, AGUINAM ET, FERRARI M, SMITH P, CHAN A, CARNELL G, OHLENDORF L, EINHAUSER S, GEORGE C, WAGNER R, TEMPERTON N, CASTILLO-OLIVARES J, BAXENDALE H, HEENEY JL#; HICC CONSORTIUM. (2021) Paucity and discordance of neutralising antibody responses to SARS-CoV-2 VOCs in vaccinated immunodeficient patients and health-care workers in the UK. Lancet Microbe. 2021 Jun 28. doi: 10.1016/S2666-5247(21)00157-9.[abstract]
  • PETERHOFF D#, THALHAUSER S, SOBCZAK JM, MOHSEN MO, VOIGT C, SEIFERT N, NECKERMANN P, HAUSER A, DING S, SATTENTAU Q, BACHMANN MF, BREUNIG M, WAGNER R#. (2021) Augmenting the Immune Response against a Stabilized HIV-1 Clade C Envelope Trimer by Silica Nanoparticle Delivery. Vaccines (Basel). 9(6):642. doi: 10.3390/vaccines9060642.[abstract]
  • WAGNER R#, PETERHOFF D*, BEILEKE S*, GÜNTHER F*, BERR M, EINHAUSER S, SCHÜTZ A, NILLER HH, STEININGER P, KNÖLL A, TENBUSCH M, MAIER C, KORN K, STARK KJ, GESSNER A, BURKHARDT R, KABESCH M, SCHEDL H, KÜCHENHOFF H, PFAHLBERG AB, HEID IM*, GEFELLER O*, ÜBERLA K#. (2021) Estimates and Determinants of SARS-Cov-2 Seroprevalence and Infection Fatality Ratio Using Latent Class Analysis: The Population-Based Tirschenreuth Study in the Hardest-Hit German County in Spring 2020. 13(6):1118. doi: 10.3390/v13061118.[abstract]
  • GREWE B, VOGT C, HORSTKÖTTER T, TIPPLER B, XIAO H, MÜLLER B, ÜBERLA K, WAGNER R, ASBACH B, BOHNE J#. (2021) The HIV 5′ Gag Region Displays a Specific Nucleotide Bias Regulating Viral Splicing and Infectivity. 2021 May 27;13(6):997. doi: 10.3390/v13060997.[abstract]
  • CARNELL GW, CIAZYNSKA KA, WELLS DA, XIONG X, AGUINAM ET, MCLAUGHLIN SH, MALLERY D, EBRAHIMI S, CERON-GUTIERREZ L, ASBACH B, EINHAUSER S, WAGNER R, JAMES LC, DOFFINGER R, HEENEY JL#, BRIGGS JAG#. (2021)  SARS-CoV-2 spike protein stabilized in the closed state induces potent neutralizing responses. J Virol. 2021 May 7:JVI.00203-21.[abstract]
  • LAINŠČEK D*, FINK T*, FORSTNERIČ V*, HAFNER-BRATKOVIČ I, OREHEK S, STRMŠEK Ž, MANČEK-KEBER M, PEČAN P, ESIH H, MALENŠEK Š, AUPIČ J, DEKLEVA P, PLAPER T, VIDMAR S, KADUNC L, BENČINA M, OMERSA N, ANDERLUH G, POJER F, LAU K, HACKER D, CORREIA BE, PETERHOFF D, WAGNER R, BERGANT V, HERRMANN A, PICHLMAIR A, JERALA R#. (2021) A Nanoscaffolded Spike-RBD Vaccine Provides Protection against SARS-CoV-2 with Minimal Anti-Scaffold Response. Vaccines (Basel). 2021 Apr 27;9(5):431. doi: 10.3390/vaccines9050431.[abstract]
  • WERNER M, PERVAN P, GLÜCK V, ZEMAN F, KOLLER M, BURKHARDT R, GLÜCK T, WENZEL JJ, SCHMIDT B, GESSNER A, PETERHOFF D#. (2021) Evaluation of a Broad Panel of SARS-CoV-2 Serological Tests for Diagnostic Use. J Clin Med. 2021 Apr 8;10(8):1580. doi: 10.3390/jcm10081580.[abstract]
  • GEIS T, BRANDSTETTER S, TONCHEVA AA, LAUB O, LEIPOLD G, WAGNER R, KABESCH M, KASSER S, KUHLE J*, WELLMANN S*# & CoKiBa Study group. (2021) Serum neurofilament light chain (sNfL) values in a large cross-sectional population of children with asymptomatic to moderate COVID-19. J Neurol. 2021 Apr 23. doi: 10.1007/s00415-021-10554-1. [abstract]
  • GLÜCK V, GROBECKER S, TYDYKOV L, SALZBERGER B, GLÜCK T, WEIDLICH T, BERTOK M, GOTTWALD C, WENZEL JJ, GESSNER A, SCHMIDT B, PETERHOFF D#. (2021) SARS-CoV-2-directed antibodies persist for more than six months in a cohort with mild to moderate COVID-19. 2021 Mar 10:1-8.[abstract]
  • DREIER E*, MALFERTHEINER MV*#, DIENEMANN T, FISSER C, FOLTAN M, GEISMANN F, GRAF B, LUNZ D, MAIER LS, MÜLLER T, OFFNER R, PETERHOFF D, PHILIPP A, SALZBERGER B, SCHMIDT B, SINNER B, LUBNOW M. (2021) ECMO in COVID-19-prolonged therapy needed? A retrospective analysis of outcome and prognostic factors. Perfusion. 2021 Feb 20:267659121995997.[abstract]
  • ZAMORA D, DUKE ER, XIE H, EDMISON BC, AKOTO BB, KIENER R, STEVENS-AYERS T, WAGNER R, MIELCAREK M, LEISENRING WM, JEROME KR, SCHIFFER J, FINAK G, DE ROSA S, BOECKH MJ#. (2021) Cytomegalovirus-specific T-cell Reconstitution following Letermovir Prophylaxis after Hematopoietic Cell Transplantation. 2021 Mar 3:blood.2020009396.[abstract]
  • WAGNER-DROUET E, TESCHNER D, WOLSCHKE C, SCHÄFER-ECKART K, GÄRTNER J, MIELKE S, SCHREDER M, KOBBE G, HILGENDORF I, KLEIN S, VERBEEK M, DITSCHKOWSKI M, KOCH M, LINDEMANN M, SCHMIDT T, RASCLE A, BARABAS S, DEML L, WAGNER R#, WOLFF D#. (2021) Comparison of Cytomegalovirus-Specific Immune Cell Response to Proteins versus Peptides Using an IFN-γ ELISpot Assay after Hematopoietic Stem Cell Transplantation Diagnostics 2021, 11(2), 312[abstract]
  • PETERHOFF D#, GLÜCK V, VOGEL M, SCHUSTER P, SCHÜTZ A, NEUBERT P, ALBERT V, FRISCH S, KIESSLING M, PERVAN P, WERNER M, RITTER N, BABL L, DEICHNER M, HANSES F, LUBNOW M, MÜLLER T, LUNZ D, HITZENBICHLER F, AUDEBERT F, HÄHNEL V, OFFNER R, MÜLLER M, SCHMID S, BURKHARDT R, GLÜCK T, KOLLER M, NILLER HH, GRAF B, SALZBERGER B, WENZEL JJ, JANTSCH J, GESSNER A, SCHMIDT B*#, WAGNER R*#. (2020) A highly specific and sensitive serological assay detects SARS-CoV-2 antibody levels in COVID-19 patients that correlate with neutralization. Infection. 2021 Feb;49(1):75-82. doi: 10.1007/s15010-020-01503-7[abstract]
  • WAGNER-DROUET E*, TESCHNER D*, WOLSCHKE C, JANSON D, SCHÄFER-ECKART K, GÄRTNER J, MIELKE S, SCHREDER M, KOBBE G, KONDAKCI M, HILGENDORF I, VON LILIENFELD-TOAL M, KLEIN S, HEIDENREICH D, KREIL S, VERBEEK M, GRASS S, DITSCHKOWSKI M, GROMKE T, KOCH M, LINDEMANN M, HÜNIG T, SCHMIDT T, RASCLE A, GULDAN H, BARABAS S, DEML L, WAGNER R#, WOLFF D#. (2021) Standardized monitoring of cytomegalovirus-specific immunity can improve risk stratification of recurrent cytomegalovirus reactivation after hematopoietic stem cell transplantation. Haematologica. 2021 Feb 1;106(2):363-374[abstract]
  • LUBNOW M#, SCHMIDT B, FLECK M, SALZBERGER B, MÜLLER T, PESCHEL G, SCHNECKENPOINTNER R, LANGE T, HITZENBICHLER F, KIENINGER M, LUNZ D, GRAF B, BROCHHAUSEN C, WEBER F, LÜKE F, PETERHOFF D, SCHUSTER P, HIERGEIST A, OFFNER R, HEHR U, WALLNER S, HANSES F, SCHMID S, WEIGAND K, GEISMANN F, POECK H, PUKROP T, EVERT M, GESSNER A, BURKHARDT R, HERR W, MAIER LS, HEUDOBLER D#. (2021) Secondary hemophagocytic lymphohistiocytosis and severe liver injury induced by hepatic SARS-CoV-2 infection unmasking Wilson’s disease: Balancing immunosuppression. Int J Infect Dis. 2021 Jan 4;103:624-627[abstract]
  • HÄHNEL V#, PETERHOFF D, BÄUERLEIN V, BROSIG AM, PAMLER I, JOHNSON C, BICA A, TOTIR M, OSSNER T, STEMMER B, TOELGE M, SCHÜTZ A, NILLER HH, SCHMIDT B, WAGNER R, GESSNER A, BURKHARD R, OFFNER R. (2020) Manufacturing of convalescent plasma of COVID-19 patients: Aspects of quality. PLoS One. 2020 Dec 22;15(12):e0243967;[abstract]
  • THALHAUSER S, PETERHOFF D, WAGNER R, BREUNIG M#. (2020) Silica particles incorporated into PLGA-based in situ-forming implants exploit the dual advantage of sustained release and particulate delivery. Eur J Pharm Biopharm. 2020 Aug 26:S0939-6411(20)30265-4.[abstract]
  • LÉVY Y#, LACABARATZ C, ELLEFSEN-LAVOIE K, STÖHR W, LELIÈVRE JD, BART PA, LAUNAY O, WEBER J, SALZBERGER B, WIEDEMANN A, SURENAUD M, KOELLE DM, WOLF H, WAGNER R, RIEUX V, MONTEFIORI DC, YATES NL, TOMARAS GD, GOTTARDO R, MAYER B, DING S, THIÉBAUT R, MCCORMACK S, CHÊNE G, PANTALEO G. (2020) Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II Trial. PLoS Pathog. 2020 Jun 26;16(6):e1008522.[abstract]
  • MOODIE Z#, WALSH SR, LAHER F, MAGANGA L, HERCE ME, NAIDOO S, HOSSEINIPOUR MC, INNES C, BEKKER LG, GRUNENBERG N, MANN P, YU C, DECAMP AC, MINER MD, YATES NL, HEPTINSTALL J, MKHIZE NN, DINTWE O, FRAHM N, COHEN KW, ALLEN M, HUTTER J, WAGNER R, PANTALEO G, MCELRATH MJ, TOMARAS GD, MORRIS L, MONTEFIORI DC, ANDERSEN-NISSEN E, GRAY GE, GILBERT PB, KUBLIN JG. (2020) Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials. PLoS Med. 2020 May 22;17(5):e1003117.[abstract]
  • MARSCHALL M#, STROJAN H, KIENER R, WANGEN C, SONNTAG E, MÜLLER R, ZEITTRÄGER I, WAGNER S, STAMMINGER T, MILBRADT J, BEHRENDS U, KÖRBER N, BAUER T, SCHRÖDEL S, THIRION C, WAGNER R, HUTTERER C. (2020) Differential upregulation of host cell protein kinases by the replication of α-, β- and γ-herpesviruses provides a signature of virus-specific signalling. J Gen Virol. 2020 Mar;101(3):284-289. doi: 10.1099/jgv.0.001370.[abstract]
2019
  • PERDIGUERO B, GÓMEZ CE, GARCÍA-ARRIAZA J, SÁNCHEZ-CORZO C, SORZANO CÓS, WILMSCHEN S, VON LAER D, ASBACH B, SCHMALZL C, PETERHOFF D, DING S, WAGNER R, KIMPEL J, LEVY Y, PANTALEO G, ESTEBAN M#. (2019) Heterologous Combination of VSV-GP and NYVAC Vectors Expressing HIV-1 Trimeric gp145 Env as Vaccination Strategy to Induce Balanced B and T Cell Immune Responses. Front Immunol. 2019 Dec 18;10:2941.[abstract]
  • GIEL-MOLONEY M#, ESTEBAN M, OAKES BH, VAINE M, ASBACH B, WAGNER R, MIZE GJ, SPIES AG, MCELRATH J, PERREAU M, ROGER T, IVES A, CALANDRA T, WEISS D, PERDIGUERO B, KIBLER KV, JACOBS B, DING S, TOMARAS GD, MONTEFIORI DC, FERRARI G, YATES NL, ROEDERER M, KAO SF, FOULDS KE, MAYER BT, BENNETT C, GOTTARDO R, PARRINGTON M, TARTAGLIA J, PHOGAT S, PANTALEO G, KLEANTHOUS H, PUGACHEV KV. (2019) Recombinant HIV-1 vaccine candidates based on replication-defective flavivirus vector. Sci Rep. 2019 Dec 27;9(1):20005.[abstract]
  • WAGNER-DROUET E*, TESCHNER D*, WOLSCHKE C, JANSON D, SCHÄFER-ECKART K, GÄRTNER J, MIELKE S, SCHREDER M, KOBBE G, KONDAKCI M, HILGENDORF I, VON LILIENFELD-TOAL M, KLEIN S, HEIDENREICH D, KREIL S, VERBEEK M, GRAß S, DITSCHKOWSKI M, GROMKE T, KOCH M, LINDEMANN M, HÜNIG T, SCHMIDT T, RASCLE A, GULDAN H, BARABAS S, DEML L, WAGNER R#, WOLFF D#. (2019) Standardized monitoring of cytomegalovirus-specific immunity can improve risk stratification of recurrent cytomegalovirus reactivation after hematopoietic stem cell transplantation. Haematologica. 2019 Dec 26. pii: haematol.2019.229252.[abstract]
  • THALHAUSER S*, PETERHOFF D*, WAGNER R#, BREUNIG M#. (2019) Critical design criteria for engineering a nanoparticulate HIV-1 vaccine. J Control Release. 2019 Nov 28. pii: S0168-3659(19)30704-7;[abstract]
  • THALHAUSER S, PETERHOFF D, WAGNER R#, BREUNIG M#. (2019) Presentation of HIV-1 Env trimers on the surface of silica nanoparticles. J Pharm Sci. 2019 Nov 1. pii: S0022-3549(19)30731-2.[abstract]
  • PANTALEO G#, JANES H, KARUNA S, GRANT S, OUEDRAOGO GL, ALLEN M, TOMARAS GD, FRAHM N, MONTEFIORI DC, FERRARI G, DING S, LEE C, ROBB ML, ESTEBAN M, WAGNER R, BART PA, RETTBY N, MCELRATH MJ, GILBERT PB, KUBLIN JG, COREY L; NIAID HIV VACCINE TRIALS NETWORK. (2019) Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial. Lancet HIV. 2019 Oct 7. pii: S2352-3018(19)30262-0.Epub ahead of print[abstract]
  • NADAI Y, HELD K, JOSEPH S, AHMED MIM, HOFFMANN VS, PETERHOFF D, MISSANGA M, BAUER A, JOACHIM A, REIMER U, ZERWECK J, MCCORMACK S, COPE AV, TATOUD R, SHATTOCK RJ, ROBB ML, SANDSTROEM EG, HOELSCHER M, MABOKO L, BAKARI M, KROIDL A, WAGNER R, WEBER J, POLLAKIS G, GELDMACHER C#. (2019) Envelope-Specific Recognition Patterns of HIV Vaccine-Induced IgG Antibodies Are Linked to Immunogen Structure and Sequence. Front Immunol. 2019 Apr 24;10:717. doi: 10.3389/fimmu.2019.00717. eCollection 2019.[abstract]
  • SCHMITT S, MONTALBÁN-LÓPEZ M, PETERHOFF D, DENG J, WAGNER R,, HELD M, KUIPERS OP#, PANKE S#. (2019) Analysis of modular bioengineered antimicrobial lanthipeptides at nanoliter scale. Nat Chem Biol. 2019 Apr 1. doi: 10.1038/s41589-019-0250-5.Epub ahead of print [abstract]
  • ASBACH B, KIBLER KV, KÖSTLER J, PERDIGUERO B, YATES NL, STANFIELD-OAKLEY S, TOMARAS GD, KAO SF, FOULDS KE, ROEDERER M, SEAMAN MS, MONTEFIORI DC, PARKS R, FERRARI G, FORTHAL DN, PHOGAT S, TARTAGLIA J, BARNETT SW, SELF SG, GOTTARDO R, CRISTILLO AD, WEISS DE, GALMIN L, DING S, HEENEY JL, ESTEBAN M, JACOBS BL, PANTALEO G, WAGNER R#. (2018) Priming with a potent HIV-1 DNA vaccine frames the quality of immune responses prior to a poxvirus and protein boost. J Virol. 2019 Jan 17;93(3). pii: e01529-18. doi: 10.1128/JVI.01529-18. Print 2019 Feb 1.[abstract]
  • KIBLER KV, ASBACH B, PERDIGUERO B, GARCÍA-ARRIAZA J, YATES NL, PARKS R, STANFIELD-OAKLEY S, FERRARI G, MONTEFIORI DC, TOMARAS GD, ROEDERER M, FOULDS KE, FORTHAL DN, SEAMAN MS, SELF S, GOTTARDO R, PHOGAT S, TARTAGLIA J, BARNETT S, CRISTILLO AD, WEISS D, GALMIN L, DING S, HEENEY JL, ESTEBAN M, WAGNER R,, PANTALEO G, JACOBS BL#. (2018) Replication-competent NYVAC-KC yields improved immunogenicity to HIV-1 antigens in rhesus macaques, compared to non-replicating NYVAC. J Virol. 2019 Jan 17;93(3). pii: e01513-18. doi: 10.1128/JVI.01513-18. Print 2019 Feb 1.[abstract]
2018
  • ASBACH B, MEIER JP, PFEIFER M, KÖSTLER J, WAGNER R. (2018) Computational Design of Epitope-Enriched HIV-1 Gag Antigens with Preserved Structure and Function for Induction of Broad CD8+T Cell Responses. Sci Rep. 2018 Jul 26;8(1):11264. [abstract]
  • WAGNER R, ASBACH B. (2018) Dürfen wir noch auf eine HIV-Impfung hoffen?MMW Fortschr Med. 2018 Jun;160(Suppl 2):24-27. [abstract]https://www.ncbi.nlm.nih.gov/pubmed/29943333 (GER)
  • KIENER R, FLEISCHMANN M, WIEGAND MA, LEMMERMANN NAW, SCHWEGLER C, KAUFMANN C, RENZAHO A, THOMAS S, FELDER E, NILLER HH, ASBACH B, WAGNER R. (2018) Efficient delivery of HCMV T cell antigens by attenuated Sendai virus vectors. J Virol.J Virol. 2018 Jul 17;92(15). [abstract]
  • BARTHOLOMAE M, BAUMANN T, NICKLING JH, PETERHOFF D, WAGNER R, BUDISA N, KUIPERS OP. (2018) Expanding the Genetic Code ofLactococcus lactis and Escherichia coli to Incorporate Non-canonical Amino Acids for Production of Modified Lantibiotics. Front Microbiol. 2018 Apr 6;9:657. [abstract]
  • KIENER R, FLEISCHMANN M, SCHWEGLER C, RUZSICS Z, THIRION C, SCHRÖDEL S, ASBACH B, WAGNER R. (2018) Vaccine vectors based on Adenovirus 19a/64 exhibit broad cellular tropism and potently restimulate HCMV-specific T cell responses ex vivo. Sci Rep. 2018 Jan 24;8(1):1474.[abstract]
2017
  • Wagner R. (2017) Effective HIV vaccine: narrow path to broadly neutralizing antibodies? Curr Opin HIV AIDS. 2017 Mar 2.[link] (COM)
  • BANAS B, STEUBL D, RENDERS L, CHITTKA D, BANAS MC, WEKERLE T, KOCH M, WITZKE O, MÜHLFELD A, SOMMERER C, HABICHT A, HUGO C, HÜNIG T, LINDEMANN M, SCHMIDT T, RASCLE A, BARABAS S, DEML L, WAGNER R, KRÄMER BK, KRÜGER B. (2017) Clinical validation of a novel ELISpot-based in vitro diagnostic assay to monitor CMV-specific cell-mediated immunity in kidney transplant recipients: a multicenter, longitudinal, prospective, observational study. Transpl Int. 2018 Apr;31(4):436-450.[abstract]
  • RANCAN F, AFRAZ Z, HADAM S, WEISS L, PERRIN H, KLICHE A, SCHRADE P, BACHMANN S, SCHÄFER-KORTING M, BLUME-PEYTAVI U, WAGNER R, COMBADIÈRE B, VOGT A. (2017) Topically applied virus-like particles containing HIV-1 Pr55gag protein reach skin antigen-presenting cells after mild skin barrier disruption. J Control Release. 2017 Oct 25. pii: S0168-3659(17)30932-X.[abstract]
  • BRUUN TH, GRASSMANN V, ZIMMER B, ASBACH B, PETERHOFF D, KLICHE A, WAGNER R. (2017) Mammalian cell surface display for monoclonal antibody-based FACS selection of viral envelope proteins. MAbs. 2017 Oct;9(7):1052-1064.[abstract]
  • JOSEPH S, QUINN K, GREENWOOD A, COPE AV, MCKAY PF, HAYES PJ, KOPYCINSKI JT, GILMOUR J, MILLER AN, GELDMACHER C, NADAI Y, AHMED MI, MONTEFIORI DC, DALLY L, BOULIOTIS G, LEWIS DJ, TATOUD R, WAGNER R, ESTEBAN M, SHATTOCK RJ, MCCORMACK S, WEBER J. (2017) A Comparative Phase I Study of Combination, Homologous Subtype-C DNA, MVA, and Env gp140 Protein/Adjuvant HIV Vaccines in Two Immunization Regimes. Front Immunol. 2017 Feb 22;8:149.[abstract]
  • BARABAS S, SPINDLER T, KIENER R, TONAR C, LUGNER T, BATZILLA J, BENDFELDT H, RASCLE A, ASBACH B, WAGNER R, DEML L. (2017) An optimized IFN-γ ELISpot assay for the sensitive and standardized monitoring of CMV protein-reactive effector cells of cell-mediated immunity. BMC Immunol. 2017 Mar 7;18(1):14.[abstract]
  • BANAS B, BÖGER CA, LÜCKHOFF G, KRÜGER B, BARABAS S, BATZILLA J, SCHEMMERER M,, KÖSTLER J, BENDFELDT H, RASCLE A, WAGNER R, DEML L, LEICHT J, KRÄMER BK. (2017) Validation of T-Track® CMV to assess the functionality of cytomegalovirus-reactive cell-mediated immunity in hemodialysis patients. BMC Immunol. 2017 Mar 7;18(1):15.[abstract]
  • ASBACH B, WAGNER R. (2017) Particle-based delivery of the HIV envelope protein. Curr Opin HIV AIDS. 2017 May;12(3):265-271[abstract] (Review)
  • PETERHOFF D, WAGNER R. (2017) Guiding the long way to broad HIV neutralization. Curr Opin HIV AIDS. 2017 May;12(3):257-264[abstract] (Review)
  • GARCÍA-ARRIAZA J, PERDIGUERO B, HEENEY JL, SEAMAN MS, MONTEFIORI DC, YATES NL, TOMARAS GD, FERRARI G, FOULDS KE, ROEDERER M, SELF SG, BORATE B, GOTTARDO R, PHOGAT S, TARTAGLIA J, BARNETT SW, BURKE B, CRISTILLO AD, WEISS DE, LEE C, KIBLER KV, JACOBS BL, WAGNER R, DING S, PANTALEO G, ESTEBAN M. (2017) HIV/AIDS vaccine candidates based on replication-competent recombinant poxvirus NYVAC-C-KC expressing trimeric gp140 and Gag-derived VLPs or lacking the viral molecule B19 that inhibits type I interferon activate relevant HIV-1-specific B and T cell immune functions in non-human primates. J Virol. 2017 Apr 13;91(9). pii: e02182-16[abstract]
2016
  • ZURAWSKI G, ZURAWSKI S, FLAMAR AL, RICHERT L, WAGNER R, TOMARAS GD, MONTEFIORI DC, ROEDERER M, FERRARI G, LACABARATZ C, BONNABAU H, KLUCAR P, WANG Z, FOULDS K, KAO SF, YATES N, LABRANCHE C, JACOBS B, KIBLER B, ASBACH B, KLICHE A, SALAZAR A, REED S, SELF S, GOTTARDO R, GALMIN L, WEISS D, CRISTILLO C, THIEBAUT R, PANTALEO G, LEVY Y. (2016) Targeting HIV-1 Env Gp140 to LOX-1 Elicits Immune Responses in Rhesus Macaques. PLoS One. 2016 Apr 14;11(4):e015348[abstract]
  • ASBACH B, KLICHE A, KÖSTLER J, PERDIGUERO B, ESTEBAN M, JACOBS BL, MONTEFIORI DC, LABRANCHE CC, YATES NL, TOMARAS GD, FERRARI G, FOULDS KE, ROEDERER M, LANDUCCI G, FORTHAL DN, SEAMAN MS, HAWKINS N, SELF SG, SATO A, GOTTARDO R, PHOGAT S, TARTAGLIA J, BARNETT SW, BURKE B, CRISTILLO AD, WEISS DE, FRANCIS J, GALMIN L, DING S, HEENEY JL, PANTALEO G, WAGNER R. (2016) Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens. J Virol. 2016 Mar 28;90(8):4133-49[abstract]
2015
  • KRINNER S, HEITZER A, ASBACH B, WAGNER R. (2015) Interplay of promoter usage and intragenic CpG content: Impact on GFP reporter gene expression. Hum Gene Ther. 2015 Dec;26(12):826-40. Epub 2015 Sep 29.[abstract]
  • GARCÍA-ARRIAZA J, PERDIGUERO B, HEENEY J, SEAMAN M, MONTEFIORI DC, LABRANCHE C, YATES NL, SHEN X, TOMARAS GD, FERRARI G, FOULDS KE, MCDERMOTT A, KAO SF, ROEDERER M, HAWKINS N, SELF S, YAO J, FARRELL P, PHOGAT S, TARTAGLIA J, BARNETT SW, BURKE B, CRISTILLO A, WEISS D, LEE C, KIBLER K, JACOBS B, ASBACH B, WAGNER R, DING S, PANTALEO G, ESTEBAN M. (2015) Head-to-head comparison of poxvirus NYVAC and ALVAC vectors expressing identical HIV-1 clade C immunogens in prime/boost combination with Env protein in non-human primates. Virol. 2015 Aug;89(16):8525-39. Epub 2015 Jun 3.[abstract]
  • PATEL P, ASBACH B, SHTEYN E, GOMEZ C, COLTOFF A, BHUYAN S, TYNER AL, WAGNER R, BLAIN SW. (2015) Brk/PTK6 phosphorylates p27Kip1, regulating the activity of cyclin D-CDK4. Mol Cell Biol. 2015 May;35(9):1506-22. Epub 2015 Mar 2.[abstract]
  • MOOIJ P, KOOPMAN G, DRIJFHOUT JW, NIEUWENHUIS IG, BEENHAKKER N, KOESTLER J, BOGERS WM, WAGNER R, ESTEBAN M, PANTALEO G, HEENEY JL, JACOBS BL, MELIEF CJ. (2015) Synthetic long peptide booster immunization in rhesus macaques primed with replication competent NYVAC-C-KC induces a balanced CD4/CD8 T-cell and antibody response against the conserved regions of HIV-1. J Gen Virol. 2015 Jun;96(Pt 6):1478-1483. Epub 2015 Feb 9.[abstract]
  • PERDIGUERO B, GÓMEZ CE, CEPEDA V, SÁNCHEZ-SAMPEDRO L, GARCÍA-ARRIAZA J, MEJÍAS-PÉREZ E, JIMÉNEZ V, SÁNCHEZ C, SORZANO CO, OLIVEROS JC, DELALOYE J, ROGER T, CALANDRA T, ASBACH B, WAGNER R, KIBLER KV, JACOBS BL, PANTALEO G, ESTEBAN M. (2015) Virological and immunological characterization of novel NYVAC-based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as VLPs. J Virol. 2015 Jan 15;89(2):970-88.[abstract]
2014
  • MCCOY LE, RUTTEN L, FRAMPTON D, ANDERSON I, GRANGER L, BASHFORD-ROGERS R, DEKKERS G, STROKAPPE NM, SEAMAN MS, KOH W, GRIPPO V, KLICHE A, VERRIPS T, KELLAM P, FASSATI A, WEISS RA. (2014) Molecular evolution of broadly neutralizing llama antibodies to the CD4-binding site of HIV-1. PLoS Pathog. 2014 Dec 18;10(12):e1004552.[abstract]
  • BRUUN TH, MÜHLBAUER K, BENEN T, KLICHE A, WAGNER R. (2014) A Mammalian Cell Based FACS-Panning Platform for the Selection of HIV-1 Envelopes for Vaccine Development. PLoS One. 2014 Oct 3;9(10):e109196.[abstract]
  • BENEN TD, TONKS P, KLICHE A, KAPZAN R, HEENEY JL, WAGNER R. (2014) Development and immunological assessment of VLP-based immunogens exposing the membrane-proximal region of the HIV-1 gp41 protein. J Biomed Sci. 2014 Aug 27;21(1):79.[abstract]
  • LAI RPJ, HOCK M, RADZIMANOWSKI J, TONKS P, HULSIK DJ, EFFANTIN G, SEILLY DJ, DREJA H, KLICHE A, WAGNER R, BARNETT SW, TUMBA N, MORRIS L, LABRANCHE CC, MONTEFIORI DC, SEAMAN MS, HEENEY JL, WEISSENHORN W. J Biol Chem. (2014) A fusion intermediate gp41 immunogen elicits neutralizing antibodies to HIV-1. 2014 Oct 24;289(43):29912-26[abstract]
  • KRINNER S, HEITZER AP, DIERMEIER SD, OBERMEIER I, LÄNGST G, WAGNER R. (2014) CpG domains downstream of TSSs promote high levels of gene expression. Nucleic Acid Res. 2014 Apr;42(6):3551-64. [abstract]
2013
  • WAGNER R, ASBACH B. (2013) Immun gegen AIDS – ein erreichbares Ziel? MMW Fortschr Med. 2013 Jun 13;155 Suppl 1:36-9.[abstract] (GER)
  • KOOPMAN G, BEENHAKKER N, NIEUWENHUIS I, DOXIADIS G, MOOIJ P, DRIJFHOUT JW, KOESTLER J, HANKE T, FAGROUCH Z, VERSCHOOR EJ, BONTROP RE, WAGNER R, BOGERS WM, MELIEF CJ. (2013) DNA/long peptide vaccination against conserved regions of SIV induces partial protection against SIVmac251 challenge. 2013 Nov 28;27(18):2841-51[abstract]
2012
  • LISS M, DAUBERT D, BRUNNER K, KLICHE K, HAMMES U, LEIHERER A, WAGNER R. (2012)Embedding permanent watermarks in synthetic genes. PLoS One. 2012;7(8):e42465. [abstract]
  • ASBACH B, LUDWIG C, SAKSELA K, WAGNER R. (2012) Comprehensive Analysis of Interactions between the Src-Associated Protein in Mitosis of 68 kDa and the Human Src-Homology 3 Proteome. PLoS One. 2012;7(6):e38540.[abstract]
  • TENBUSCH M, IGNATIUS R, NCHINDA G, TRUMPFHELLER C, SALAZAR AM, TÖPFER K, SAUERMANN U, WAGNER R, HANNAMAN D, TENNER-RACZ K, RACZ P, STAHL-HENNIG C, UBERLA K. (2012) Immunogenicity of DNA vaccines encoding simian immunodeficiency virus antigen targeted to dendritic cells in rhesus macaques. PLoS One.2012;7(6):e39038. [abstract]
  • JUNGLAS B, KUESPERT S, SELEEM AA, STRULLER T, ULLMANN S, BÖSL M, BOSSERHOFF A, KÖSTLER J, WAGNER R, TAMM ER, FUCHSHOFER R. (2012) Connective Tissue Growth Factor Causes Glaucoma by Modifying the Actin Cytoskeleton of the Trabecular Meshwork.Am J Pathol. 2012 Jun;180(6):2386-403. [abstract]
  • GÓMEZ CE, PERDIGUERO B, JIMÉNEZ V, FILALI-MOUHIM A, GHNEIM K, HADDAD EK, QUAKKERLAAR ED, DELALOYE J, HARARI A, ROGER T, DUNHEN T, SÉKALY RP, MELIEF CJ, CALANDRA T, SALLUSTO F, LANZAVECCHIA A, WAGNER R, PANTALEO G, ESTEBAN M. (2012) Systems Analysis of MVA-C Induced Immune Response Reveals Its Significance as a Vaccine Candidate against HIV/AIDS of Clade C. PLoS One. 2012;7(4):e35485.[abstract]
  • BÖCKL K, WILD J, BREDL S, KINDSMÜLLER K, KÖSTLER J, WAGNER R. (2012) Altering an Artificial Gagpolnef Polyprotein and Mode of ENV Co-Administration Affects the Immunogenicity of a Clade C HIV DNA Vaccine. PLoS One. 2012;7(4):e34723.[abstract]
  • NOTKA F, WAGNER R. (2012) Reprogramming a GFP Reporter Gene Subjects It to Complex Lentiviral Gene Regulation. Methods Mol Biol. 2012;813:85-106.[abstract]
2011
  • KINDSMÜLLER K, WAGNER R. (2011) Synthetic biology: Impact on the design of innovative vaccines. Hum Vaccin. 2011 Jun 1;7(6):658-62;[abstract] (COM)
  • FREISCHMIDT A, LISS M, WAGNER R, KALBITZER HR, HORN G. (2011) RNA secondary structure and in vitro translation efficiency. Protein Expr Purif. 2012 Mar;82(1):26-31;[abstract]
  • KIBLER KV, GOMEZ CE, PERDIGUERO B, WONG S, HUYNH T, HOLECHEK S, ARNDT W, JIMENEZ V, GONZALEZ-SANZ R, DENZLER K, HADDAD EK, WAGNER R, SÉKALY RP, TARTAGLIA J, PANTALEO G, JACOBS BL, ESTEBAN M. (2011) Improved NYVAC-Based Vaccine Vectors. PLoS One., 6(11):e25674;[abstract]
  • AGWALE SM, FORBI JC, NOTKA F, WRIN T, WILD J, WAGNER R, WOLF H. (2011) Broad Antibody Mediated Cross-Neutralization and Preclinical Immunogenicity of New Codon-Optimized HIV-1 Clade CRF02_AG and G Primary Isolates. PLoS One., 6(8):e23233;[abstract]
  • PERREAU M, WELLES HC, HARARI A, HALL O, MARTIN R, MAILLARD M, DORTA G, BART PA, KREMER EJ, TARTAGLIA J, WAGNER R, ESTEBAN M, LEVY Y, PANTALEO G. (2011) DNA/NYVAC Vaccine Regimen Induces HIV-Specific CD4 and CD8 T-Cell responses in Intestinal Mucosa. J Virol., 85(19):9854-62;[abstract] 
  • NOTKA F, LISS M, WAGNER R. (2011) Industrial scale gene synthesis. Methods Enzymol., 498:247-75;[abstract]
  • FLYNN BJ, KASTENMÜLLER K, WILLE-REECE U, TOMARAS GD, ALAM M, LINDSAY RW, SALAZAR AM, PERDIGUERO B, GOMEZ CE, WAGNER R, ESTEBAN M, PARK CG, TRUMPFHELLER C, KELER T, PANTALEO G, STEINMAN RM, SEDER R. (2011) Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates. Proc Natl Acad Sci USA, 108(17):7131-6;[abstract]
  • FATH S, BAUER AP, LISS M, SPRIESTERSBACH A, MAERTENS B, HAHN P, LUDWIG C, SCHÄFER F, GRAF M, WAGNER R. (2011) Multiparameter RNA and Codon Optimization: A Standardized Tool to Assess and Enhance Autologous Mammalian Gene Expression. PLOS One, 6(3):e17596;[abstract]
2010
  • KOSOVAC D, WILD J, LUDWIG C, MEISSNER S, BAUER AP, WAGNER R. (2010) Minimal doses of a sequence-optimized transgene mediate high level and longterm EPO expression in vivo: challenging CpG-free gene design. Gene Ther., 18(2):189-98.[abstract]
  • ASBACH B, KOLB M, LISS M, WAGNER R, SCHÄFERLING M. (2010) Protein Microarray Assay for the Screening of SH3 Domain Interactions. Anal Bioanal Chem., 398(5):1937-46;[abstract]
  • HOFMANN-SIEBER H, WILD J, FIEDLER N, TISCHER K, VON EINEM J, OSTERRIEDER N, HOFMANN H, KÖSTLER J, WAGNER R. (2010) Impact of ETIF Deletion on Safety and Immunogenicity of EHV-1 Vectored Vaccines. J Virol., 84(22):11602-13;[abstract]
  • RAAB D, GRAF M, NOTKA F, SCHÖDL T, WAGNER R. (2010) The GeneOptimizer Algorithm: Using a sliding window approach to cope with the vast sequence space in multiparameter DNA sequence optimization. Syst Synth Biol., 4(3):215-25;[abstract]
  • FREISCHMIDT A, MEYSING M, LISS M, WAGNER R, KALBITZER HR, HORN G. (2010) Limiting factors of the translation machinery. J Biotechnol., 150(1):44-50;[abstract]
  • MAERTENS B, SPRIESTERSBACH A, VON GROLL U, ROTH U, KUBICEK J, GERRITS M, GRAF M, LISS M, DAUBERT D, WAGNER R, SCHÄFER F. (2010) Gene optimization mechanisms: A multi-gene study reveals a high success rate of full-length human proteins expressed in Escherichia coli. Protein Sci., 19(7):1312-1326;[abstract]
  • BAUER AP, LEIKAM D, KRINNER S, NOTKA F, LUDWIG C, LÄNGST G, WAGNER R. (2010) The impact of intragenic CpG content on gene expression. Nucleic Acids Res., 38(12):3891-908;[abstract]
  • GACH JS, FURTMÜLLER PG, QUENDLER H, MESSNER P, WAGNER R, KATINGER H, KUNERT R. (2010) Proline is not uniquely capable of providing the pivot point for domain swapping in 2G12, a broadly neutralizing antibody against HIV-1. Biol. Chem., 285(2):1122-7;[abstract]
2009
  • MGC PROJECT TEAM, TEMPLE G, GERHARD DS, RASOOLY R, FEINGOLD EA, GOOD PJ, ROBINSON C, MANDICH A, DERGE JG, LEWIS J, SHOAF D, COLLINS FS, JANG W, WAGNER L, SHENMEN CM, MISQUITTA L, SCHAEFER CF, BUETOW KH, BONNER TI, YANKIE L, WARD M, PHAN L, ASTASHYN A, BROWN G, FARRELL C, HART J, LANDRUM M, MAIDAK BL, MURPHY M, MURPHY T, RAJPUT B, RIDDICK L, WEBB D, WEBER J, WU W, PRUITT KD, MAGLOTT D, SIEPEL A, BREJOVA B, DIEKHANS M, HARTE R, BAERTSCH R, KENT J, HAUSSLER D, BRENT M, LANGTON L, COMSTOCK CL, STEVENS M, WEI C, VAN BAREN MJ, SALEHI-ASHTIANI K, MURRAY RR, GHAMSARI L, MELLO E, LIN C, PENNACCHIO C, SCHREIBER K, SHAPIRO N, MARSH A, PARDES E, MOORE T, LEBEAU A, MURATET M, SIMMONS B, KLOSKE D, SIEJA S, HUDSON J, SETHUPATHY P, BROWNSTEIN M, BHAT N, LAZAR J, JACOB H, GRUBER CE, SMITH MR, MCPHERSON J, GARCIA AM, GUNARATNE PH, WU J, MUZNY D, GIBBS RA, YOUNG AC, BOUFFARD GG, BLAKESLEY RW, MULLIKIN J, GREEN ED, DICKSON MC, RODRIGUEZ AC, GRIMWOOD J, SCHMUTZ J, MYERS RM, HIRST M, ZENG T, TSE K, MOKSA M, DENG M, MA K, MAH D, PANG J, TAYLOR G, CHUAH E, DENG A, FICHTER K, GO A, LEE S, WANG J, GRIFFITH M, MORIN R, MOORE RA, MAYO M, MUNRO S, WAGNER S, JONES SJ, HOLT RA, MARRA MA, LU S, YANG S, HARTIGAN J, GRAF M, WAGNER R, LETOVKSY S, PULIDO JC, ROBISON K, ESPOSITO D, HARTLEY J, WALL VE, HOPKINS RF, OHARA O, WIEMANN S. (2009) The completion of the Mammalian Gene Collection (MGC). Genome Res. 2009 Dec;19(12):2324-33;[abstract]
  • WILD J, BIELER K, KÖSTLER J, FRACHETTE MJ, JEFFS S, VIEIRA S, ESTEBAN M, LILJESTRÖM P, PANTALEO G, WOLF H, WAGNER R. (2009) Preclinical evaluation of the immunogenicity of C-type HIV-1-based DNA and NYVAC vaccines in the Balb/C mouse model. Viral Immunol. 22(5):309-19;[abstract]
  • LEIHERER A, LUDWIG C, WAGNER R. (2009) Uncoupling HIV-1 gag and pol reading frames: Role of the transframe protein p6* in viral replication. J. Virol.,83(14):7210-20;[abstract]
  • MOOIJ P, BALLA-JHAGJHOORSINGH SS, BEENHAKKER N, VAN HAAFTEN P, BAAK I, NIEUWENHUIS IG, HEIDARI S, WOLF H, FRACHETTE MJ, BIELER K, SHEPPARD N, HARARI A, BART PA, LILJESTRÖM P, WAGNER R, PANTALEO G, HEENEY JL. (2009) Comparison of human and rhesus macaque T-cell responses elicited by boosting with NYVAC encoding HIV-1 clade C immunogens. J. Virol., 83(11):5881-9;[abstract]
  • LEIHERER A, LUDWIG C, WAGNER R. (2009) Influence of extended mutations of the HIV-1 transframe protein p6 on Nef-dependent viral replication and infectivity in vitro. Virology, 387(1):200-10;[abstract]
  • MINSHULL J, WAGNER R. (2009) Preventing the misuse of gene synthesis. Biotechnol. 27(9):800-801;[link] (COM)
2008
  • GRAF M, SCHOEDL T, WAGNER R (2009) Rationales of Gene Design and De Novo Gene Construction. In: Systems Biology and Synthetic Biology, eds. Fu P, Latterich M, Panke S. Wiley-Interscience, ISBN 0471767786, Chapter 12:407-434 (ENG)
  • KREUTER A, POTTHOFF A, BROCKMEYER NH, GAMBICHLER T, STÜCKER M, ALTMEYER P, SWOBODA J, PFISTER H, WIELAND U; GERMAN COMPETENCE NETWORK HIV/AIDS (Collaborator: WAGNER R). (2008) Imiquimod leads to a decrease of human papillomavirus DNA and to a sustained clearance of anal intraepithelial neoplasia in HIV-infected men. J Invest Dermatol, 128(8):2078-83;[abstract]
  • SPETH C, BREDL S, HAGLEITNER M, WILD J, DIERICH M, WOLF H, SCHROEDER J, WAGNER R, DEML L. (2008) Human immunodeficiency virus type-1 (HIV-1) Pr55(gag) virus-like particles are potent activators of human monocytes. Virology, 382(1):46-58;[abstract]
  • BART PA, GOODALL R, BARBER T, HARARI A, GUIMARAES-WALKER A, KHONKARLY M, SHEPPERD N,  BANGALA Y, FRACHETTE MJ, WAGNER R, LILJESTROM P, KRAHENBUHL JP, GIRARD M, GOUDSCHMIDT J, ESTEBAN M, HEENEY J, SATTENTAU Q, MCCORMACK S, BABIKER A, PANTALEO G, WEBER J. (2008) EV01: A Phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium. Vaccine 13;26(25):3153-61;[abstract]
  • MCCORMACK S, STÖHR W, BARBER T, BART PA, HARARI A, MOOG CH, CIUFFREDA D, CELLERAI CH, COWEN M, GAMBONI R, BURNET S, LEGG K, BRODNICKI E, WOLF H, WAGNER R, HEENEY J, FRACHETTE MJ, TARTAGLIA J, BABIKER A, PANTALEO G, WEBER J. (2008) EV02: A Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone. Vaccine 13;26(25):3162-74;[abstract]
  • VERSTREPEN BE, BINS AD, ROLLIER CS, MOOIJ P, KOOPMAN G, SHEPPARD NC, SATTENTAU Q, WAGNER R, WOLF H, SCHUMACHER TN, HEENEY JL, HAANEN JB. (2008) Improved HIV-1 specific T-cell responses by short-interval DNA tattooing as compared to intramuscular immunization in non-human primates. Vaccine 26(26):3346-51;[abstract]
  • HAMMER D, WILD J, LUDWIG C, ASBACH B, NOTKA F, WAGNER R. (2008) Fusion of EBNA1-Derived Gly-Ala Repeat to Transdominant HIV-1 Gag Increases Inhibitory Activities and Survival of Transduced Cells In Vivo. Hum Gene Ther 19(6):622-34;[abstract]
  • STOLTE-LEEB N, BIELER K, KÖSTLER J, HEENEY J, TEN HAAFT P, SUH Y, HUNSMANN G, STAHL-HENNIG C, WAGNER R. (2008) Better Protective Effects in Rhesus Macaques by Combining Systemic and Mucosal Application of a Dual Component Vector Vaccine After Rectal SHIV89.6P Challenge Compared to Systemic Vaccination Alone. Viral Immunol 21(2):235-46;[abstract]
  • LUDWIG C, LEIHERER A, WAGNER R. (2008) Importance of protease cleavage sites within and flanking HIV-1 transframe protein p6* for spatiotemporal regulation of protease activation. J Virol 82(9):4573-84;[abstract]
  • CORBETT M, BOGERS W, HEENEY JL, GERBER S, GENIN C, DIDIERLAURENT A, OOSTERMEIJER H, DUBBES R, BRASKAMP G, LERONDEL S, GOMEZ CE, ESTEBAN M, WAGNER R, KONDOVA I, MOOIJ P, BALLA-JHAGJHOORSINGH J, BEENHAKKER N, KOOPMAN G, VAN DER BURG S, KRAEHENBUHL JP, LE PAPE A. (2008) Aerosol immunization with NYVAC and MVA vectored vaccines is safe, simple, and immunogenic. Proc Natl Acad Sci USA 105(6):2046-51;[abstract]
  • HARARI A, BART PA, STÖHR W, TAPIA G, GARCIA M, MEDJITNA-RAIS E, BURNET S, CELLERAI C, ERLWEIN O, BARBER T, MOOG C, LILJESTROM P, WAGNER R, WOLF H, KRAEHENBUHL JP, ESTEBAN M, HEENEY J, FRACHETTE MJ, TARTAGLIA J, MCCORMACK S, BABIKER A, WEBER J, PANTALEO G. (2008) An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med 205(1):63-77;[abstract]
  • MOOIJ P, BALLA-JHAGJHOORSINGH SS, KOOPMAN G, BEENHAKKER N, VAN HAAFTEN P, BAAK I, NIEUWENHUIS I, KONDOVA I, WAGNER R, WOLF H, GÓMEZ CE, NÁJERA JL, JIMÉNEZ V, ESTEBAN M, HEENEY JL. (2008) Differential CD4+ versus CD8+ T-cell responses elicited by different Poxvirus-based HIV-1 vaccine candidates provide comparable efficacy in primates. J Virol 82(6):2975-88;[abstract]
  • GOLDWICH A, HAHN SSC, SCHREIBER S, MEIER S, KÄMPGEN E, WAGNER R, LUTZ M, SCHUBERT U. (2008) Targeting HIV-1 Gag into the Defective Ribosomal Product Pathway Enhances MHC Class I Antigen Presentation and CD8+ T Cell Activation. J Immunol 180(1):372-82;[abstract]
2007
  • LUDWIG C, WAGNER R (2007) Virus-like Particles – Universal Molecular Toolboxes. Curr Opin Biotechnol 18(6):537-45;[abstract] (ENG)
  • HEIKKINEN LS, KAZLAUSKAS A, MELEN K, WAGNER R, ZIEGLER T, JULKUNEN I, SAKSELA K. (2007) Avian and 1918 Spanish influenza A virus NS1 proteins bind to Crk/CrkL SH3 domains to activate host cell signalling. JBC 29;283(9):5719-27;[abstract]
  • HARARI A, CELLERAI C, BELLUTTI ENDERS F, KÖSTLER J, CODARRI L, TAPIA G, BOYMAN O, CASTRO E, GAUDIERI S, JAMES I, JOHN M, WAGNER R, MALLAL S, PANTALEO G. (2007) Skewed association of polyfunctional antigen-specific CD8 T cell populations with HLA-B genotype. PNAS 104(41):16233-8;[abstract]
  • BÜGL H, DANNER JP, MOLINARI RJ, MULLIGAN JT, PARK H-O, REICHERT B, ROTH DA, WAGNER R, BUDOWLE B, SCRIPP RM, SMITH JAL, STEELE SJ, CHURCH G, ENDY D (2007) DNA synthesis and biological security. Nat Biotechnol 25(6):627-629;[abstract]
  • KESTI T, RUPPELT A, WANG J-H, LISS M, WAGNER R, KJETIL T, SAKSELA K (2007) Reciprocal regulation of SH3 and SH2 domain binding via tyrosine phosphorylation of a common site in CD3e. J Immunol 179(2):878-85;[abstract]
  • LARKE N, IM EJ, WAGNER R, WILLIAMSON C, WILLIAMSON AL, McMICHAEL AJ, HANKE T (2007) Combined single-clade candidate HIV-1 vaccines induce T cell responses limited by multiple forms of in vivo immune interference. Eur J Immunol. 37(2):566-77[abstract]
  • LESCHONSKY B, LUDWIG C, BIELER K, WAGNER R (2007) Capsid stability and replication of human immunodeficiency virus I are influenced critically by charge and size of Gag residue 183. J Gen Virol 88:207-16;[abstract]
  • GOMEZ CE, NAJERA JL, JIMENEZ V, BIELER K, WILD J, KOSTIC L, HEIDARE S, CHEN M, FRACHETTE MJ, PANTALEO G, WOLF H, LILJESTROEM P, WAGNER R, ESTEBAN M (2007) Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C. Vaccine 25:1969-92;[abstract]
  • GOMEZ CE, NAJERA JL, PEREZ JIMENEZ E, JIMENEZ V, WAGNER R, GRAF M, FRACHETTE MJ, LILJESTROEM P, PANTALEO G, ESTEBAN M (2007) Head-to-head comparision of the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1 BX08 gp120 and HIV-1 IIIB Gag-Pol-Nef proteins of clade B. Vaccine 25:2863-85[abstract]
2006
  • GRAF M, LUDWIG C, KEHLENBECK S, JUNGERT K, WAGNER R (2006) A quasi-lentiviral green fluorescent protein reporter exhibits nuclear export features of late human immunodeficiency virus type 1 transcripts. Virology 352(2):295-305;[abstract]
  • KUATE S, STAHL-HENNIG C, STOIBER H, NCHINDA G, FLOTO A, FRANZ M, SAUERMANN U, BREDL S, DEML L, IGNATIUS R, NORLEY S, RACZ P, TENNER-RACZ K, STEINMAN RM, WAGNER R, ÜBERLA K (2006) Immunogenicity and Efficacy of Immunodeficiency Virus-Like Particles Pseudotyped with the G protein of Vesicular Stomatitis Virus. Virology 351(1):133-44;[abstract]
  • KARKKAINEN S, HIIPAKKA M, WANG JH, KLEINO I, VAHA-JAAKKOLA M, RENKEMA GH, LISS M, WAGNER R, SAKSELA K (2006) Identification of preferred protein interactions by phage-display of the human Src homology-3 proteome. EMBO 7(2):186-91;[abstract]
2005
  • DEML L, SPETH C, DIERICH MP, WOLF H, WAGNER R (2005) Recombinant HIV-1 Pr55(gag) virus-like particles: potent stimulators of innate and acquired immune responses. Mol Immunol 42:259-277;[abstract] (ENG)
  • SIGERT S, THALERT S, WAGNER R, SCHNIERLE BS (2005) Assessment of HIV-1 entry inhibitors by MLV/HIV-1 pseudotyped vectors. AIDS Res Ther 12;2-7;[abstract]
  • KOOPMAN G, MORTIER D, NIPHUIS H, FARESE AM, KAHN LE, MANN D, WAGNER R, MACVITTIE TJ, WOULFE SL, HEENEY JL (2005) Systemic mobilization of antigen presenting cells, with a chimeric Flt-3 and G-CSF receptor agonist, during immunization of Macaca mulatta with HIV-1 antigens is insufficient to modulate immune responses or vaccine efficacy. Vaccine 23(33):4195-202;[abstract]
  • TRAPP S, von EINEM J, HOFMANN H, KÖSTLER J, WILD J, WAGNER R, BEER M, OSTERRIEDER N (2005) Potential of Equine Herpesvirus 1 as a vector for immunization. J Virol 79:5445-5454;[abstract]
2004
  • PAULUS C, LUDWIG C, WAGNER R (2004) Contribution of the Gag-Pol transframe domain p6* and its coding sequence to morphogenesis and replication of human immunodeficiency virus type 1. Virology 330:271-83;[abstract]
  • NOTKA F, MEIER G, WAGNER R (2004) Concerted inhibitory activities of Phyllanthus amarus on HIV replication in vitro and ex vivo. Antiviral Res 64:93-102;[abstract]
  • DIDIERLAURENT A, RAMIREZ JC, GHERARDI M, ZIMMERLI SC, GRAF M, ORBEA HA, PANTALEO G, WAGNER R, ESTEBAN M, KRAEHENBUHL JP, SIRARD JC (2004) Attenuated poxviruses expressing a synthetic HIV protein stimulate HLA-A2-restricted cytotoxic T-cell responses. Vaccine 22:3395-403;[abstract]
  • WILD J, BOJAK A, DEML L, WAGNER R (2004) Influence of polypeptide size and intracellular sorting on the induction of epitope-specific CTL responses by DNA vaccines in a mouse model. Vaccine 22:1732-43;[abstract]
  • MOOIJ P, NIEUWENHUIS IG, KNOOP CJ, DOMS RW, BOGERS WM, TEN HAAFT PJ, NIPHUIS H, KOORNSTRA W, BIELER K, KÖSTLER J, MOREIN B, CAFARO A, ENSOLI B, WAGNER R, HEENEY JL (2004) Qualitative T-helper responses to multiple viral antigens correlate with vaccine-induced immunity to simian/human immunodeficiency virus infection. J Virol 78:3333-42;[abstract]
  • GRUNWALD T, PEDERSEN FS, WAGNER R, UBERLA K (2004) Reducing mobilization of simian immunodeficiency virus based vectors by primer complementation. J Gene Med (2):147-54;[abstract] 
2003
  • WILD J, WAGNER R. (2003) Stand und gegenwärtige Strategien der HIV-Vakzineentwicklung. Internist 44:711-718[abstract] (GER)
  • DEML L, WILD J, WAGNER R (2003) Virus-like particles: a novel tool for the induction and monitoring of both T-helper and cytotoxic T-lymphocyte activity. Methods Mol Med 94:133-57;[abstract] (ENG)
  • GRAF M, DEML L, WAGNER R (2003) Codon-optimized genes that enable increased heterologous expression in mammalian cells and elicit efficient immune responses in mice after vaccination of naked DNA. Methods Mol Med 94:197-210; [abstract] (ENG)
  • DEML L, WILD J, WAGNER R (2003) Virus-like particles: a novel tool for the induction and monitoring of both T-helper and cytotoxic T-lymphocyte activity. Methods Mol Med 94:133-57;[abstract]
  • GRAF M, DEML L, WAGNER R (2003) Codon-optimized genes that enable increased heterologous expression in mammalian cells and elicit efficient immune responses in mice after vaccination of naked DNA. Methods Mol Med 94:197-210;[abstract]
  • WILD J, WAGNER R (2003) Status and current strategies of HIV vaccine development. Internist (Berl) 44:711-8;[abstract]
  • KOFMAN A, GRAF M, DEML L, KHARAZOVA A, WOLF H, WAGNER R (2003) Co-influence of transgene expression in mammalian cells. Mutual influence of transgenes on their expression in mammalian cells. Tsitologiia (4):387-91;[abstract]
  • KOFMAN A, GRAF M, BOJAK A, DEML L, BIELER K, KHARAZOVA A, WOLF H, WAGNER R (2003) HIV-1 gag expression is quantitatively dependent on the ratio of native and optimized codons. Tsitologiia (1):86-93;[abstract]
  • NOTKA F, MEIER GR, WAGNER R (2003) Inhibition of wild-type human immunodeficiency virus and reverse transcriptase inhibitor-resistant variants by Phyllanthus amarus. Antiviral Res. 58:175-86;[abstract] 
2002
  • JASSOY C, WAGNER R. (2002) Perspektiven für die Entwicklung einer HIV Vakzine. Deutsches Ärzteblatt 99:A-1962-1971[abstract] (GER)
  • BOJAK A, DEML L, WAGNER R (2002) Past, present and future of HIV-vaccine development: A critical view. Drug Discovery Today. 7:18-28;[abstract](ENG)
  • BOJAK A, WILD J, DEML L, WAGNER R (2002). Impact of Codon Usage Modification on T Cell Immunogenicity and Longevity of HIV-1 Gag-Specific DNA Vaccines. Intervirology 45: 275-286;[abstract]
  • LOTTI B, WENDLAND T, FURRER H, YAWALKAR N, VON GREYERZ S, SCHNYDER K, BRANDES M, VERNAZZA P, WAGNER R, NGUYEN T, ROSENBERG E, PICHLER WJ, BRANDER C (2002). Cytotoxic HIV-1 p55gag-specific CD4+ T cells produce HIV-inhibitory cytokines and chemokines.J Clin Immunol 22(5):253-62; [abstract]
  • INDRACCULO S, HABELER W, STIEVANO L, PIOVAN E, WAGNER R, ÜBERLA K, CHIECO-BIANCHI L, AMADORI A (2002). Gene transfer in ovarian cancer cells: A comparison between retroviral and lentiviral vectors. Cancer Research. Cancer Research 62:6099-107;[abstract]
  • KUATE S, WAGNER R, ÜBERLA K (2002) Development and characterization of a minimal inducible packaging cell line for simian immunodeficiency virus-based lentiviral vectors. J. Gene. Med. 4:347-55;[abstract]
  • HEINTEL T, SESTER M, BARTOLOMÉ RODRÍGUEZ M, KRIEG C, SESTER U, WAGNER R, PEES H, GÄRTNER B, MAIER R,  MEYERHANS A (2002) The fraction of perforin-expressing HIV-specific CD8 T cells is a marker for disease progression in HIV infection. AIDS 16:1497-501;[abstract]
  • BOJAK A, WILD J, WOLF H, WAGNER R (2002) Efficiency of a myogenic DNA vaccine is strictly dependent upon cellular localization of HIV-1 Pr55gag. Vaccine. 20:1980-1984;[abstract]
  • BOJAK A, HAMMER D, WOLF H, WAGNER R (2002) Muscle specific versus ubiquitous expression of Gag based HIV-1 vaccines: a comparative analysis. Vaccine 20:1975-1979;[abstract]
2001
  • WAGNER R. (2001) Neue Impulse für die Biotechnologie durch synthetische Gene. Bioforum 9:610-611 (GER)
  • WAGNER R, SCHMIDT, GRAF M, SCHLEEF M. (2001) Optimierte DNA Vakzine und Gentherapievektoren. BioForum 11:824-826 (GER)
  • WAGNER R. (2001) Automatisierte Gensynthese als Platfrorm für die entwicklung automatisierter Bioprod. BioForum 7/8: 488 (GER)
  • WAGNER R, Graf M (2001) Improved safety and efficiency profiles of lentiviral vectors and DNA vaccines by synthetic genes. BioTech International. 13:20-21 (ENG)
  • BIELER K, WAGNER R (2001) Synthetic genes for prevention and therapy: Implications on safety and efficacy of DNA vaccines and lentiviral Vectors. in: Plasmids for Therapy and Vaccination. ed. Martin Schleef. Wiley-VCH. ISBN 3.527-30269-7. Chapter 9:147-168 (ENG)
  • DEML L, BOJAK A, STECK S, GRAF M, WILD J, SCHIRMBECK R, WOLF H, WAGNER R (2001) Multiple effects of codon usage optimization on the expression and immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus type 1 (HIV-1) Gag protein. J.Virol. 75:10991-11001;[abstract]
  • BUONAGURO L, BUONAGURO F, TOMESELLO M, MANTAS D, BETH-GIRALDO E, WAGNER R, MICHELSON S, PREVOST M, WOLF H, GIRALDO G (2001) High efficient production of Pr55gag virus-like particles expressing multiple HIV-epitopes including a gp120 protein derived from an Ugandan HIV-1 isolate of subtype A. Antiviral Res. 49:35-47;[abstract]
2000
  • WAGNER R, GRAF M, BIELER K, WOLF H, GRUNWALD T, FOLEY P, ÜBERLA K (2000) Rev-independent expression of synthetic gag-pol genes of HIV-1 and SIV:Implications for the safety of lentiviral vectors. Human Gene Therapy 11:2403-13;[abstract]
  • SESTER M, SESTER U, KÖHLER H, SCHNEIDER T, DEML L, PEES H, WAGNER R, MEYERHANS A (2000) Rapid whole blood analysis of antigen specific CD4+ and CD8+ T-cell responses against protein immunogens in vitro: Application for the analysis of persistent HIV infection. AIDS 14:2653-2650;[abstract]
  • PIYASIRISILP S, MCCUTCHAN FE, CARR JK, SANDERS-BUELL E, CHEN J, WAGNER R, WOLF H, SHAO Y, LAI S, BEYRER C, YU XF (2000) A recent outbreak of human immunodeficiency virus type 1 infection in southern china was initiated by two highly homogeneous, geographically separated strains, circulating recombinant form AE and a novel BC recombinant. J Virol. 74:11286-95;[abstract]
  • GRAF M, BOJAK A, DEML L, WOLF H, WAGNER R (2000) Concerted action of multiple cis-acting sequences is required for Rev dependence of late human immunodeficiency virus type 1 gene expression. J. Virol. 74:10822-10826;[abstract]
  • SU L, GRAF M, VON BRIESEN H, XING H, KÖSTLER J, MELZL H, WOLF H, SHAO Y, WAGNER R (2000) Cloning and characterization of virtually full-length HIV genome of a prevalent intersubtype (C/B’) recombinant strain in China. J. Virol. 74:11367-11376;[abstract]
  • PALIARD X, LIU Y, WAGNER R, WOLF H, BAENZINGER J, WALKER CM (2000) Priming of strong, broad and long-lived HIV-1p55gag -specific CTL following administration of a virus-like particle vaccine in rhesus macaques. AIDS Research and Human Retroviruses 3:273-282;[abstract]
1999
  • FITZON T, LESCHONSKY B, PAULUS C, WOLF H, WAGNER R (1999) The NH2-terminal core domain of the HIV-1 p24 capsid mojety is involved in early steps of the viral life cycle. Virology 268:294-307
  • NOTKA F, STAHL-HENNIG C, DITTMER U, WOLF H, WAGNER R (1999) Accelerated clearance of SHIV in rhesus monkeys by virus-like particle vaccines is dependent on the induction of neutralizing antibodies. Vaccine 18:291-301
  • PAULUS C, HELLEBRAND S, TEESMER U, WOLF H, KRÄUßLICH HG, WAGNER R (1999) Competitive inhibition of the HIV-1 protease by the viral transframe protein p6*. Journal of Biological Chemistry 274:21539-21543
  • DEML L, SCHIRMBECK R, REIMANN J, WOLF H, WAGNER R (1999) Purification and characterization of hepatitis B virus surface antigen particles produced in Drosophila Schneider-2 insect cells. J. Virol. Methods 79:205-217
  • DEML L, WOLF H, WAGNER R (1999) High level expression of Hepatitis-B-Virus surface antigen in stable transfected Drosophila Schneider-2 cells. J. Virol. Methods 79:191-103
  • DEML L, SCHIRMBECK R, REIMANN J, WOLF H, WAGNER R (1999) Immunostimulatory CpG motifs trigger a T-helper 1 immune response to human immunodeficiency virus type 1 (HIV-1) gp160 envelope proteins. Clin. Chem. 37:199-204
  • HEENEY J, AKERBLOM L, BARNETT S, BOGERS W, BRUCK C, DAVID D, FULLER D, KOOPMAN G, LEHNER, T, MOOIJ P, MOREIN B, MORGHEN C, ROSENWIRTH B, VERSCHOOR E, VOSS G, WAGNER R, WOLF H (1999) HIV-1 vaccine induced immune responses which correlate with protection from SHIV infection. Immunology letters 66:189-195
  • NOTKA F, STAHL-HENNIG C, DITTMER U, WOLF H, WAGNER R (1999) Construction and characterization of recombinant VLPs and Semliki-Forest virus live vectors for comparative evaluation in the SHIV monkey model. Biol. Chem. 380:341-352
  • WAGNER R, SHAO Y, WOLF H (1999) Correlates of protection, antigen delivery and molecular epidemiology: Basics for designing an HIV vaccine. Vaccine 17:1706-1710
  • WAGNER R, LESCHONSKY B, HARRER E, PAULUS C, WEBER C, WALKER BD, BUCHBINDER S, WOLF H, KALDEN JR, HARRER T (1999) Molecular and functional analysis of a conserved CTL epitope in HIV-1 p24 recognized by CTL from a long term non progressor: Constrains on the immune escape by targeting an epitope essentially involved in viral replication. J. Immunol. 162:3727-34
1998
  • WAGNER R, DEML L. (1998) Fortschritte und Probleme bei der Entwicklung eines HIV-Impfstoffs. in: AIDS und HIV-Infektionen: Diagnostik, Klinik, Behandlung; Handbuch und Atlas für Klinik und Praxis. (H. Jäger Ed.), Ecomed Verlag II-3.5; Seite 1-12 (GER)
  • LESCHONSKY B, DEML L, NOTKA F, GRAF M, WOLF H, WAGNER R (1998) Learning from long-term non-progressing HIV infected individuals for HIV vaccine design. Italian Biochemical Society Transactions. 11:118-122 (ENG)
  • DEML L, GRAF M, LESCHONSKY B, BOJAK A, BIELER K, SU L, WOLF H, WAGNER R (1998) Strategies to improve the efficacy of particulate HIV-1 subunit vaccines for future field studies. (Polly Roy and Claude Leclerc eds.). Proceedings of EC Biotechnology and Vaccinology. 2:89-92 (ENG)
  • WOLF H, NOTKA F, DEML L, LESCHONSKY B, WALKER B, HARRER T, WAGNER R (1998) Role of the gag-specific cytotoxic T-lymphozytes during HIV-pathogenesis: Implications for the development of virus-like particle based HIV vaccines. in: Retroviruses of human AIDS and related animal diseases. (Marc Girard, Betty Dodet, eds) Colloque Des Cent Gardes. 179-185 (ENG)
  • HARRER T, HARRER E, BARBOSA P, KAUFMANN F, WAGNER R, BRÜGGEMANN S, KALDEN JR, FEINBERG M, JOHNSON RO, BUCHBINDER S, WALKER BD (1998) Recognition of two overlapping CTL epitopes in HIV-1 p17 by CTL from a long-term non-progressing HIV-1 infected individual. J. Immunol. 161: 4875-4881
  • BUONAGURO L, BUONAGURO FM, RUSSO F, TORNESELLO ML, BETH-GIRALDO E, WOLF H, WAGNER R, GIRALDO G (1998) Biomolecular characterization of a novel gp120 coding sequence from an Ugandan HIV-1 isolate of the A clade containing a large sequence insertion in the V4 major variable region. Aids Res. Hum Retroviruses 14:1287-1289
  • WAGNER R, TEEUWSEN VJ, DEML L, NOTKA F, HAAKSMA AGM, JHAGJHOORSINGH SS, NIPHIUS H, WOLF H, HEENEY JH (1998) Cytotoxic T cells and neutralizing antibodies induced in rhesus monkeys by virus-like particle HIV-1 vaccines in the absence of protection from SHIV infection. Virology 245: 65-74
  • GRAF M, SHAO Y, Zhao Q, SEIDL T, WOLF H, WAGNER R (1998) Cloning and characterization of an almost full length molecular clone of a Thai subtype B’ virus strain isolated from an asymptomatic intravenous drug abuser south of china. Aids Res. Hum. Retroviruses 14:285-288
  • NOTKA F, WAGNER R. (1997) HIV, Chemokine und Rezeptoren: Neue Aspekte zur HIV-Pathogenese. Immunität und Infektion. 105-114 (GER)
  • WAGNER R, DEML L. (1997) HIV-Impfstoffentwicklung: Quo vadis? in: AIDS – Neue Perspektiven, therapeutische Erwartungen, die Realität 1997. (H. Jäger ed.) Ecomed Verlag. 6:44-50 (GER)
1997
  • DEML L, KRATOCHWIL G, OSTERRIEDER N, KNÜCHEL R, WOLF H, WAGNER R (1997) Increased incorporation of chimeric human immunodeficiency virus type 1 gp120 proteins into pr55gag virus-like particles by an Epstein Barr virus gp220/350 derived transmembrane domain. Virology 235:10-25
  • DEML L, SCHIRMBECK R, REIMANN J, WOLF H, WAGNER R (1997) Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytolytic T-cells and neutralizing antibodies. Virology 235:26-39
1996
  • WAGNER R, REISCHL U. (1996) Qualitativer und quantitativer  Nukleinsäurenachweis in der molekularen Diagnostik von Infektionskrankheiten. Bedeutung der Virusbelastung bei der HIV Infection. (H. Jäger ed.). Thieme Verlag, 48-59 (GER)
  • DEML L, WOLF H, WAGNER R (1996) Recombinant Drosophila Schneider -2 cells as a novel tool to produce recombinant antigens for diagnostic, therapeutic and preventive purposes. in: Molecular Biology-Based Methods in Clinical Diagnosis. (Reischl, U. ed.). The Humana Press Inc. 11:185-199 (ENG)
  • BEISINGER M, PAULUS C, BEIER P, WOLF H, RÖSCH P, WAGNER R (1996) Sequence specific resonance assignments of the 1H-NMR spectra and structural characterization in solution of the HIV-1 transframe protein p6* purified under native conditions. European J. Biochemistry 237:383-392
  • WAGNER R, DEML L, NOTKA F, WOLF H, SCHIRMBECK R, REIMANN J, TEEUWSEN V, HEENEY J (1996). Safety and immunogenicity of recombinant HIV-1 particles in rodents and rhesus Macaques. Intervirology 39:93-104
  • WAGNER R, DEML L, SCHIRMBECK R, NIEDRIG M, REIMANN J, WOLF H (1996) Construction, expression and immunogenicity of chimeric HIV-1 virus-like particles. Virology 220:128-140
  • WAGNER R, DEML L, TEEUWSEN V, HEENEY J, YIMING S, WOLF H (1996) A recombinant HIV-1 virus-like particle vaccine: From concepts to a field study. Antibiot. Chemother. 48:68-83
1995
  • WAGNER R, DEML L, FITZON T, WOLF H (1995) HIV morphogenesis: Target for antiviral therapy and basis for the development of a rationally designed candidate vaccine. (Chanock, R.M., Ginsberg, H.S., Brown, F., Lerner, R.A., eds). Modern approaches to new vaccines including prevention of AIDS. CSH Laboratory press. Vaccines. 347-356 (ENG)
  • WAGNER R, DEML L, SCHIRMBECK R, REIMANN J, WOLF H (1995) Induction of a MHC class I restricted, CD8 positive cytotoxic T cell response by chimeric HIV-1 virus-like particles in vivo: Implications on HIV vaccine development. Modern Vaccine Design, (F.R. Seiler and G. Schulz eds), Behring Communications. 95:23-34 (ENG)
  • WAGNER R, WOLF H (1995) New concepts in HIV-vaccine development. The Microbiologist. 6:4-12 (ENG)
  • SCHIRMBECK R, DEML L, MELBER K, WOLF H, WAGNER R, REIMANN J (1995) Priming of Class I-restricted cytotoxic T-lymphocytes by vaccination with recombinant protein antigens without adjuvants. Vaccine 13:857-865
  • OSTERRIEDER K, WAGNER R, BRANDMÜLLER C, SCHMIDT P, WOLF H, KAADEN OR (1995) Protection against EHV-1 Challenge infection in the murine model after vaccination with various formulations of recombinant glycoprotein gp14 (gB). Virology. 208:500-510
  • BORBE H, STUBER G, WAGNER R, WOLF H, MODROW S (1995) Structural and immunological reactivity of the principle neutralizing determinant V3 of gp120/HIV-1. Journal of Peptide Science 1:109-123
  • WAGNER R, REISCHL U. (1995) Neue virologische und immunologische Aspekte der HIV-Infektion. ARZT und Fortbildung. 7:203-209 (GER)
  • WAGNER R, MAYER J, WOLF H. (1995). HIV-Pathogenese und Langzeitüberlebende: Auswirkungen auf Therapie und Impfstoffentwicklungen. Deutsche Medizinische Wochenschrift DMW. 120:728-736 (GER)
  • WAGNER R, MAYER J, REISCHL U. (1995) Labordiagnostik der HIV-Infektion. Fortschritte der Medizin. 10:39-45 (GER)
  • JÄGER H, WAGNER R. (1995) Zur Bedeutung der Virusquantifizierung bei der Behandlung der HIV-Infektion. Deutsches Ärzteblatt. 50:3545-3548 (GER)
  • WAGNER R, REISCHL U. (1995) Neue virologische und immunologische Aspekte der HIV-Infektion. in: HIV-Medizin: Möglichkeiten der individualisierten Therapie. Wissenschaftliche Ergebnisse in der Mitte der 90er Jahre. (H. Jäger ed.) Ecomed Verlag. 4:31-40 (GER)
1994
  • MAYER J, REISCHL U, WAGNER R. (1994) Labordiagnostik der HIV-Infektion. Labormedizin. 17:12-17 (GER)
  • WAGNER R, WOLF H, DEML L. (1994) AIDS, Hepatitis, Tumorviren: Ansätze für die Entwicklung neuartiger Impfstoffe. Blick in die Wissenschaft. 4: 62-72 (GER)
  • WOLF H, MODROW S, WAGNER R (1994) The HIV-1 Pr55gag Protein: Understanding the mechanism of virus assembly as a basis for the development of novel therapeutics and vaccines. in: Retroviruses of human AIDS and related animal diseases. (Marc Girard, Louis Valette, eds) Colloque Des Cent Gardes. 299-307 (ENG)
  • DEML L, ROßHUBER S, WOLF H, WAGNER R (1994) High level expression and characterization of hepatitis B-virus surface antigen in stable transfected Drosophila Schneider 2 cells. BioForum 32-35 (ENG)
  • WAGNER R, DEML L, WOLF H (1994) Polyvalent, recombinant HIV-virus-like particles: Novel HIV vaccine strategies. Antibiot Chemother 46:48-61
  • MODROW S, KATTENBECK B, VON POBLOTZKI A, NIEDRIG M, WAGNER R, WOLF H (1994) The gag proteins of human immunodeficiency virus type 1: mechanisms of virus assembly and possibilities for interference. Medical Microbiology and Immunology 183:177-194
  • OSTERRIEDER K, WAGNER R, PFEFFER M, KAADEN O (1994) Expression of glycoprotein gp14 of equine herpesvirus I (EHV-I) in E. Coli and in insect cells: A comparative study on protein processing and human immune response. Gen. Virol. 75:2041-2046
  • WAGNER R, DEML L, FLIEßBACH H, WANNER G, WOLF H (1994) Assembly and extracellular release of chimeric Pr55gag retrovirus-like particles. Virology 200:162-175
1993
  • SCHWARZMANN F, WAGNER R, MAYER J, REISCHL U, WOLF H. (1993) Aktuelle Perspektiven in der molekularen Virologie. Infektion und Immunität. 21:159-164 (GER)
  • WAGNER R, BÖLTZ T, KOSZINOWSKI U, NIEDRIG M, MODROW S, WOLF H (1993) Immunological reactivity of a consensus sequence of the HIV-1 principal neutralizing determinant V3. Peptides. 1993. (Schneider C.H. and Eberle A.N. eds), ESCOM Science Publishers, B.V. 900-902 (ENG)
  • NIEDRIG M, BICKHARD H, GELDERBLOM H, PAULI G, MODROW S, V. POBLOTZKI A, WAGNER R, WOLF H (1993) Assembly of HIV-gag proteins: A target for antiviral therapy? (Chanock, R.M., Ginsberg, H.S., Brown, F., Lerner, R.A., eds). Modern approaches to new vaccines including prevention of AIDS. CSH Laboratory press. Vaccines. 93: 209-214 (ENG)
  • BORBE H, WAGNER R, STUBER G, HABAZETTL J, HOLAK TA, WOLF  H, MODROW S (1993) The V3-loop of gp120/HIV-1: Structural, functional and immunological characterization. Peptides. 1992. (Schneider C.H. and Eberle A.N. eds), 1993 ESCOM Science Publishers, B.V. 571-572 (ENG)
  • MODROW S, V. POBLOTZKI A, WAGNER R, GELDERBLOM A, PAULI G, WOLF H, NIEDRIG M (1993) Assembly of HIV-1 gag-proteins: A new target for antiviral peptide therapy? Peptides. 1992. (Schneider C.H. and Eberle A.N. eds), 1993 ESCOM Science Publishers, B.V.  133-135 (ENG)
  • BAVAND MR, WAGNER R, RICHMOND TJ (1993) HIV-1 reverse transcriptase: Polymerization properties of the p51 homodimer compared to the p66/p51 heterodimer. Biochemistry 32:10543-10552
  • POBLOTZKI A, WAGNER R, WANNER G, NIEDRIG M, WOLF H, MODROW S (1993) Identification of a region in the Pr55gag-polyprotein essential for HIV-1 particle formation. Virology 193: 981-985
  • WAGNER R, BÖLTZ T, DEML, L, MODROW S, WOLF H (1993) Induction of cytolytic T-lyphocytes directed towards the V3-loop of the HIV-1 external glycoprotein gp120 by p55gag/V3 chimeric vaccinia viruses. Gen. Virol. 74:1261-1269
1992
  • WAGNER R, MODROW S, BÖLTZ T, FLIEßBACH H, NIEDRIG M, V. BRUNN A, WOLF H (1992) Immunological reactivity of a human immunodeficiency virus type 1 derived peptide representing a consensus sequence of the gp120 major neutralizing region V3. Virol. 127:139-152
  • WAGNER R, FLIEßBACH H, WANNER G, MOTZ M, NIEDRIG M, DEBY G, V. BRUNN A, WOLF H (1992) Studies on processing, particle formation and immunogenicity of the HIV-1 gag-gene product: A possible component of a HIV vaccine. Virol. 127:117-137